Molecular basis of cell cycle control: p300 and pRb by Chan, Ho Man
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Molecular Basis of Cell Cycle Control: p300 and pRb
Ho Man Chan
to
The Institute of Biomedical and Life Sciences, 
University of Glasgow
for the degree of 
Doctor of Philosophy
September 2000
Division of Biochemistry and Molecular Biology 
Institute of Biomedical and Life Science 
University of Glasgow
ProQuest Number: 10647230
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uesL
ProQuest 10647230
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
Abstract
The retinoblastoma protein (pRb) and p300 are transcriptional co-repressor and 
co-activator respectively, playing key roles in regulating the cell cycle. Both molecules 
are targeted by a number of viral oncoproteins, suggesting that the functional 
inactivation of these molecules is required for oncogenicity. Furthermore, p300 has an 
intrinsic histone acetyltransferase activity (HAT), which is crucial to its function. Here, 
studies were performed to understand how acétylation and de-acetylation may 
influence cell cycle regulation. I demonstrated that pRb is a substrate of p300 HAT 
activity. Furthermore, adenovirus E lA  re-directs p300 HAT activity and enhances pRb 
acétylation. Acetylated pRb preferentially binds to proto-oncoprotein MDM2, 
indicating the functional relevance of this modification in regulating pRb function. 
Acétylation of pRb also influences its phosphorylation pattern, implying a certain level 
of ‘cross-talk’ between these two post-translational modification events.
In an attempt to understand the underlying m echanism  of p300-mediated 
transcriptional co-activation, I investigated its interaction with a newly identified 
binding-partner NAP-2 (nucleosome assembly protein 2). First, the domains of 
interaction between these two proteins were studied. Subsequently, both NAP-2 and 
p300 were found to augment in transcriptional regulation. Overall, the results suggested 
a mechanism by which p300 and NAP family proteins co-operate in chromatin- 
remodeling related mechanisms in regulating transcription.
Finally, a series of pRb B pocket mutants were created, one of which was 
significantly compromised in binding to LXCXE peptide motif, including histone
deacetylases (HDACs). pR b’s growth suppressive function was correlated to its 
intrinsic repressive activity on transcription. At least in part, this intrinsic repressive 
activity was described by its association with HDACs. Using this mutant, I analysed 
the necessity of HD AC association for pRb mediated G1 arrest. Surprisingly, the 
results suggested that HD AC may be dispensable for such function. Therefore, it re­
addresses the question of the functional significance of the pRb-HDAC interaction.
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Chapter 1: Introduction
One classical approach to study cell cycle regulation is through the understanding of 
how viral oncoproteins disrupt normal cell cycle control. Three small DNA tumour viruses, 
adenovirus (Ad), simian virus 40 (SV40), and human papillomaviruses (HPVs), all encode 
genes which are capable of activating cell cycle functions in quiescent cells (reviewed in 167, 
and references therein). In this thesis, I have focused on two cellular polypeptides, pRb and 
p300, which are targets of Ad ElA  (182, reviewed in 42 and 118). In SV40, the large T 
antigen (LT) binds to pRb and p300 (reviewed in 118). In HPVs, E7 and E6 were shown to 
interact with pRb and p300 respectively (reviewed in 118).
A converging theme is that different viral oncoproteins evolve similar strategies to 
interact with pRb and p300, suggesting these two proteins play an intimate part in cell cycle 
regulation. In the early nineties, through the studies of cellular targets of viral proteins, E2F 
was identified to be important for pRb function (reviewed in 43, 62, 91, 118, 175 and 
references therein). This finding opened up an exciting era of E2F research, pinpointing its 
crucial role in transcriptional regulation of the cell cycle.
After the cloning of p300 in 1994 (44), sequence homology comparison immediately 
identified p300 as ‘a transcriptioinal adaptor protein for certain complex transcriptional 
regulatory elements’ (44). The real explosion of the field came in late 1996 when p300 was 
identified to be a bona fide  histone acetyltransferase (12, 128). p300/CBP was also found to 
interact with an ever increasing list of transcription factors, including various hormonal 
receptors (e.g estrogen receptor (ER), Retinoic acid receptor (RAR), glucocorticoid receptor 
(GR), etc.), differentiation factors (e.g. MyoD, c-MyB, GATA-1), and cell cycle regulators 
(e.g. p53, E2F, NFkB, Mdm2) (reviewed in 147, and reference therein). Furthermore,
p300/CBP interacts with RNA helicase A, which in turn binds to RNA polymerase II (Pol II), 
suggesting p300/CBP could be part of the basal transcriptional machinery (124).
Whilst our knowledge on pRb and p300 keeps accumulating, key questions remain as 
to why viral oncoproteins interact with these two cellular polypeptides. Ad ElA, for example, 
sequesters both pRb and p300 via an N-terminal transformation sensitive domain (118). 
Mutagenesis studies suggested that E lA  requires binding to both pRb and p300 for efficient 
transformation. The first model suggests that binding of E lA  (or other viral proteins, e.g. 
SV40 LT) to pRb and p300 simply inactivates their cellular functions. Studies on pRb 
support this simple model. For example, binding of ElA  to pRb disrupts pRb/E2F complex, 
thereby de-regulating E2F-dependent transcription (reviewed 43, 118, 169). However, a 
similar model may not be sufficient to explain the interactions with p300. p300''' mice have 
defects in cellular proliferation (189). Furthermore, p300 is a versatile transcription co­
activator (147). It is unlikely viral proteins simply abolish all p300 functions. Therefore, a 
second model suggests that viral oncoproteins may activate or re-direct a normal cellular 
activity in dis-regulating cell cycle control. For example, E lA  may recruit p300 to activate its 
growth promoting functions. Since E lA  was demonstrated to form a ternary complex 
between pRb and p300 (173), a third possibility also exists that viral oncoproteins mediate 
the assembly of novel complex(es) to run havoc with the cell cycle.
In the following chapters, I will first review current literature on pRb and p300. In 
chapter three, evidence will be presented that pRb can be a substrate of p300 HAT activity, 
suggesting a direct functional interaction between these two cellular polypeptides. In chapter 
four, work will be presented on a nucleosome assembly protein which was found to associate 
with p300, pointing towards another level of p300-mediated transcriptional control. In 
chapter five, the functional interaction between pRb and HDACs will be explored. Finally, I 
will summarise the key findings, and discuss the possible implications.
The Retinoblastoma Protein (pRb)
The retinoblastoma protein is a llOKDa nuclear phosphoprotein. It is a classical 
tumour suppressor. Functional inactivation of both copies of the Rb gene is an invariant 
feature of both sporadic and familial retinoblastomas (reviewed In 134). Young children with 
a germ-line mutation in one Rbl allele have a 95% chance of developing a retinoblastoma 
tumour in their eyes. Mutation in the Rbl allele also predisposes patients to develop other 
tumours, such as osteosarcomas and fibrosarcomas. Almost two-thirds of the secondary 
tumours arising in patients with retinoblastoma are mesenchymal in origin. Dryja, Friend and 
Weinberg (40) cloned the 4.7Kb cDNA corresponding to the R bl gene. The Rbl gene 
contains 27 exons, spanning across 180kb on chromosome 13. Most mutations in Rbl lead to 
premature termination of translation.
pRb and its family members
The pRb, pl07 and p i30 proteins form the ‘pocket protein (PP)’ family that is crucial 
to cell cycle regulation (reviewed in 99, 134, 174 and 181). pRb and pl07/pl30 have five 
highly conserved domains. pRb shares between 30-35% sequence identity with pl07/pl30. 
Most of the conserved sequences lie within the so-called ‘pocket region’ (amino acid 379- 
792), which is composed of two subdomains, known as the ‘A ’ and ‘B’ boxes. Viral 
oncoproteins, SV40 LT, ad ElA  and ‘high risk’ HPVs E7 all target the pocket domain, 
displacing cellular proteins which interact with the pocket, thereby leading to loss of pocket 
protein function.
Negative growth 
signals
Positive growth 
signals
CDKI
AP-1, 
MyoD, 
NF-IL6, etc.
CDK
Rb
E2F
MDM2 p53
differentiation S phase entry apoptosis apoptosis
Fig. 1.1 pRb integrates negative and positive signals with the cell cycle clock.
Mitogenic signals activate cyclin-dependent kinase activity and inactivate pRb function by 
phosphorylation. In reverse, inhibitory signals, such as TGF(3 and contact inhibition mobilise CDK 
inhibitors (CDKI) to maintain active pRb in its hypophosphorylated form. pRb has at least two 
distinct activities in tumour suppression: by inactivating downstream E2F activity, and by augmenting 
transcription activities of various transcription factors for cellular differentiation. MDM2 acts as a 
mediator bridging together the p53 and pRb pathways.
At least three distinct protein-binding activities of pRb have been described to be 
important for its function: the large pocket (amino acid 395-876) binds to E2F (discussed 
later), the small pocket (amino acid 379-792) binds to the LXCXE (L = leucine, C = cysteine, 
E = glutamic acid, X = any amino acid) peptide, and the C pocket binds to tyrosine kinase c- 
Abl and oncoprotein MDM2 (176, 183 and reviewed in 174). Viral oncoproteins e.g. ElA, 
E7, SV40 LT and some cellular proteins e.g. HDACs, cyclin D, possess an LXCXE motif in 
their protein sequence that enables them to bind to the pocket. The three dimensional 
structure of the pRb A/B pocket bound to an LXCXE containing peptide from E7 has been 
solved (94). The peptide binds to a highly conserved groove on the B box portion of the 
pocket, and the A box is required for the stable folding of the B box. The A/B box interface is 
highly conserved, suggesting an additional protein-binding region. Furthermore, both E2F 
and E7 peptides occupy distinct sites in the pocket. HDACs, which contain an LXCXE-like 
motif, may form a trimeric complex with pRb and E2F (19, 103). c-Abl can bind to pRB 
when the pocket region is occupied by E2F (183). Taken together, the evidence suggests a 
model for pRb as a ‘molecular matchmaker’ in mediating protein complex formation 
(reviewed in 174).
Despite the close similarities among the family members, only Rb was shown to be 
mutated in tumour cells. Neither p l0 7  nor p l3 0  were frequently found to be mutated in 
naturally occurring tumours. In order to study the specific cellular function of pRb, p i07 and 
p i 30, knock out mice in R b ,p l0 7  and p i 30 have been developed. The phenotypes indicated 
both distinct and over-lapping functions among the family members (32, 33, 73, 93, 95 and 
reviewed in 99 and 120). The absence of pRb in mice causes embryonic lethality, although 
p l0 7 ‘^' and p i  30' '^ mice survive to term, possibly as a result of functional redundancy between 
pl07 and pl30. This is consistent with the phenotype of the pl07'''':pl30"'' mice which exhibit
embryonic lethality. Interestingly, Rb^^' mice do not suffer from retinoblastoma, but develop 
tumours of the pituitary and thyroid origin. This difference may be attributable to the 
physiology of humans and mice. Bilateral, multifocal retinal dysplasia is indeed observed in 
Rb^^'\pl07'^' mice. This suggests that pRb and p i07 may share overlapping functions in 
controlling cellular homeostasis in the murine retina, and loss of both is required for tumour 
formation, p i 07'^':p 130^''' and p i 07^^’:p 130'^' mice were developed to investigate whether 
p i07 and p i 30 possess tumour suppression function. However, analysis of such animals did 
not reveal any obvious tumour phenotype. An alternative explanation is that unlike the 
mutations in pRb, mutations in p i07 and/or p i30 may not be advantageous for 
tumour gene sis. Therefore mutations in other components of the pathway, such as pi 6 (86), 
which is indeed frequently found to be mutated in human tumour(s), may contribute to the 
inactivation of pl07/pl30 tumour suppression function, without abrogating other essential 
functions of pl07/pl30.
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Fig. 1.2 The pocket protein family and the functional domains in pRb.
a) A schematic organisation of pRb, p l07  and pl30 is shown. Regions conserved among the three 
pocket proteins are highlighted in black. Shaded areas indicate additional regions of similarity 
between p i07 and p i30.
b) Functional and biochemical domains within pRb are indicated that are required for interacting with 
the LXCXE motif, E2F, MDM2/c-Abl, and functionally required for growth suppression. The A 
and B domains constitute the pocket domain of pRb, and the C pocket is indicated.
Cell cycle regulation of pRb
pRb/E2F
The pRb protein is ubiquitously expressed in most cycling and resting cells. pRb acts
as a negative regulator for cellular proliferation, sequestering a variety of nuclear proteins 
progression
involved in cell c y c l e ; . ( r e v i e w e d  in 175). The most studied pRb target is the family of 
transcription factors known as E2F (reviewed in 43, 91). E2F consists of a heterodimer of an 
E2F protein bound to a DP partner. Together, they regulate the timing and levels of 
expression of many genes involved in cell cycle progression (reviewed in 62, and references 
therein). E2F target genes encode proteins involved in DNA replication (for example DNA 
polymerase a , thymidine kinase (TK), dihydrofolate reductase (DHFR) and cdc6), 
chromosomal replication (for example replication origin-binding protein HsOrcl, MCM 
proteins) and cell cycle regulation (for example cyclin A, E and D l, p i07, cdc2, E2F1, 4 and 
5 and p i 9^ "^ ). One important feature of E2F DNA-binding site is that in many promoters 
(including B-myb, E2F-1, cyclin E, cyclin A, ORCl, cdc2, cdc6), E2F DNA-binding sites 
contribute to transcription repression, presumably through the assembly of the E2F/PP 
repression complex on these promoters. Indeed, in vivo footprinting experiments obtained on 
cdc2 and B-myb promoters demonstrated E2F DNA-binding site occupation during GO to 
early G l, when the E2Fs are in transcriptional repressive complexes with the PPs (162, 199). 
A few activating E2F DNA binding sites were also identified, which include p i07, DHFR 
and TK (reviewed in 62, and references therein).
A simple working model for how pRb regulates E2F function suggests that during 
GO/Gl, hypophosphorylated pRb binds to E2F, inactivating it and thereby preventing cell 
cycle progression (reviewed in 115, also see later). Cyclin D/cdk4/6 and cyclin E/cdk2 
progressively phosphorylate pRb at late G l to early S phase. In S phase, pRb phosphorylation
is maintained by cycHn A/cdk2. Progressive phosphorylation of pRb results in reduced 
affinity for E2Fs, the release of free E2F and thereafter induction of E2F transcription.
Different FPs have a preference for binding to different E2F family members 
(reviewed in 62, and references therein). The E2F family now consists of six members (E2F- 
1 to 6). E2F-1, 2 and 3 exhibit high affinity binding towards pRb, but bind weakly to 
pl07/pl30. In contrast, E2F-4 and 5 show greater specificity for pl07/pl30, but also bind 
pRb. Complexes between the pRb family members and E2F form at different phases of the 
cell cycle. In general, pl30/E2F complexes are mainly found in quiescent or differentiated 
cells, pl07/E2F complexes predominate in S phase cells, and pRb/E2F complexes are most 
evident during Gl/S phase transition, but also exist in quiescent or differentiated cells (69, 
117 and reviewed in 43 and 62). Using chromatin immunoprécipitation assays, it was found 
that repression on E2F-responsive promoters was associated with the recruitment of E2F-4 
and pl30, together with low level of histone acétylation (190). In late G1 phase, the E2F- 
4/pl30 complex is replaced by E2F-1 and E2F-3, together with enhanced level of acétylation 
of histones H3 and H4. Taken together, it seems that distinct E2F heterodimers recruit 
enzymes to deacetyl ate or acetylate core histones, therefore repressing or activating E2F- 
responsive genes (190),
pRb can modulate E2F transcription activity in at least two distinct ways (reviewed 
in 43). Firstly, pRb binds to the transcription activation domain in E2F and directly inhibits 
E2F-mediated transcription. Using in vitro transcription and footprinting assays, Ross et. al. 
(138) demonstrated that pRb blocks the recruitment of the transcription initiation complex by 
E2F. Secondly, pRb binds to HD AGs (19, 103, and 106), which is believed to deacetylate 
histones on the promoter, and actively repress transcription via chromatin remodelling. Zhang 
et. al. (197) demonstrated that active repression of the pRb/E2F complex is important in 
mediating G1 arrest triggered by transforming growth factor-p (TGFp), p i6 and contact
inhibition. Interestingly, a trimeric complex of pRb-HDAC-hSWI/SNF has recently been 
demonstrated (196). The hSWI/SNF complex also has chromatin remodelling activity, 
implying a third mechanism for pRb modulation of E2F transcription activity. Furthermore, 
the pRb-hSWI/SNF complex can exist in the absence of HD AC, and this complex is 
sufficient to repress cyclin A and cdc2 genes, but not cyclin E or E2F-1 genes (196). 
Therefore, pRb-HDAC-hSWESNF and pRB-hSWI/SNF could be two distinct complexes, 
acting at different phases of the cell cycle and regulating the expression of different sets of 
gene.
Apart from regulating E2F transcription, pRb and its family members also regulate 
E2F protein stability, cellular localisation and apoptotic function (reviewed in 43, 62). E2F-1 
is actively degraded by the ubiquitin-proteosome pathway through an SCF-like complex 
(107). E2F-1 mutants which cannot be degraded by the SCF pathway drive cell cycle 
progression into S phase followed by apoptosis. Unphosphoiylated pRb stabilised E2F-1 and 
protects it from degradation (61, 63). E2F-1 mediated apoptosis is both p53-dependent and - 
independent (130). Ecotopic expression of E2F-1 causes apoptosis in SA0S2 cell, which is a 
p53''' cell line, suggesting this apoptotic mechanism is p53-independent (65, 130). The 
apoptotic function seems to be specific to E2F-1 since overexpression of E2F-2 and E2F-3 
failed to induce apoptosis, even though they induced the expression of E2F target genes and 
drove cells into S phase (35). Phillips et. al. (131) demonstrated that E2F-1 mediated 
apoptosis can at least in part occur through a death receptor-dependent mechanism by 
inhibiting activation of anti-apoptotic signals including NF-kB. Analysis of the E2F-1 
mutants indicates that the apoptotic function is independent of its transcriptional activation 
domain, but requires DNA binding (65, 130). Over-expression of pRb overcomes E2F-1 
mediated apoptosis.
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While E2F-1, 2 and 3 protein levels change according to the cell cycle, being peak at 
late G1 to early S phase and degrading after S phase; E2F-4 and 5 protein levels stay 
relatively constant in different phases of the cell cycle (96, 107). From extracts of tissue 
culture cells, it is E2F-4 which contributes the bulk of E2F DNA-binding activity. E2F-4 is 
both nuclear and cytoplasmic in quiescent cells, but relocates almost entirely to the cytoplasm 
when the cells reach S phase. Expression of DP-2, pl07 and p i 30 was reported to drive 
nuclear localisation of E2F-4 (36, 98, 105).
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a) activating complex
E2F/DP
b) inhibiting complex
E2F/DP/PP
r
c) repressing complex
HDAC
E2F/DP/PP
hSWI/SNF
Fig 1.3 Pocket proteins have multiple modes o f regulation in controlling 
E2F DNA-binding sites.
There are at least three types of E2F complex: an activating E2F complex, an 
inhibiting E2F complex and a repressing E2F complex (43).
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Phosphorylation Control o f pRb
The pRb function is controlled by phosphorylation during the cell cycle (reviewed in 
115). In its active state, pRb is hypophosphorylated, which occurs in early G1 phase o f  the 
cycling cells. Hyperphosphorylated pRb, which shows retarded migration in SDS gel, is 
generated in late G1 to S phase, and correlates with inactivation o f  pRb. Phosphorylation o f  
pRb in late G1 was carried out by a combination o f  cyclin/CDKs, and type 1 protein 
phosphatase (P P l) was found to dephosphorylate pRb in late mitosis (reviewed in 115).
Kinases
E/cdk2 A/cdk2
D/cdk4 
D/cdk6
Phosphatase
PPl
pRb
G1 02 M 0 1
Fig 1.4 pRb activity is controlled by phosphorylation and dephosphorylation during the 
cell cycle.
Hypophosphorylated pRb is active in growth repression. Phosphorylation of pRb in late G1 by a 
combination of cyclin/CDKs converts pRb to an inactive hyperphosphorylated form. Dephosphorylation 
of pRb in late mitosis by type 1 protein phosphatase (PPl) restores pRb growth suppressive activity 
(115).
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pRb contains 16 S/T-P motifs which are potential CDK phosphorylation sites. At 
least seven of those sites (S-249, -807, -811, and T-252, -373, -821, -826) were shown to be 
phosphorylated in vivo (84, 85 and references therein). Cyclin D- and cyclin E- activated 
kinase complexes phosphorylate pRb on different sites in vitro, neither one being sufficient to 
phosphorylate the full set of sites that is seen in in vivo (115). Phosphorylation of certain sites 
of pRb was demonstrated to carry specific functions. For example, phosphorylation at S807 
and -811 was shown to release the interaction of c-Abl from pRb (84). The binding of pRb to 
E2F is regulated by a number of sites in the C-terminus of pRb, and possibly involves two 
serines in the linker region between the A and B boxes (85, 168).
The three dimensional structure of the pRb A/B pocket in complex with the E7 
peptide identified a highly conserved lysine patch in B pocket which could function as 
phospho-receptor sites (94). Harbour et al. (59) presented evidence that phosphorylation of 
the pRb C-terminus by CDK4/6 causes successive intramolecular interactions between the C- 
terminus and the central pocket region, presumably via the lysine patch. The initial 
interaction is thought to disrupt HDAC binding, and therefore relieves active repression by 
pRb. This event then facilitates the phosphorylation of the pocket region by cyclin E/CDK2, 
thereby disrupting the pRb/E2F interaction. These intramolecular interactions provide a 
molecular basis for how phosphorylation alters pRb protein structure, and progressively 
inactivates its growth suppression function.
Anti-apoptotic function of pRb
As discussed above, over-expression of E2F-1 causes apoptosis in SAOS2 cells. Co­
expression of pRb protects cells from E2F-1 mediated apoptosis, which depends upon the 
ability of pRb to bind to E2F-1. Conversely, cells lacking pRb leads to inappropriate S-phase
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entry, activation of E2F responsive genes, and apoptosis (3). Several tissues in the Rb''' mice 
display extensive cell death. The analysis of the Rb'‘'' mouse embryos versus the E2F~r^':Rb'^' 
embryos also indicated that pRb suppresses E2F-1 mediated apoptosis (see below, 167, 186, 
187 and reviewed in 99 and 120). Interestingly, one report suggested that pRb could promote 
apoptosis by forming a trimeric complex with MDM2 and p53 (64). pRb was shown to 
antagonise MDM2 mediated p53 degradation, stabilising p53, and restoring p53 trans­
repression and apoptotic function. However, p53 /ra«jactivation was not rescued in those 
assays. Interleukin 1 P-converting enzyme-like (ICE-like) protease was found to cleave off the 
C-terminus of pRb in response to tumour necrosis factor (TNF)- and staurosporin-induced 
apoptosis (135). Cleaved pRb still bound to E2F-1 and cyclin D, but lost binding to MDM2. 
Therefore, the pRb/MDM2 interaction is likely to affect the apoptotic function of pRb, 
though it is not clear if this interaction is pro- or anti- apopotosis.
Role in terminal differentiation
A role for pRb in differentiation was suggested by the phenotype of Rb'''' mice, which 
show a pronounced defect in erythroid, neuronal and lens development (reviewed in 99, 120). 
Although loss of pRb function allows the initiation of differentiation, the embryos fail to 
achieve a fully differentiated state, indicating that pRb is likely to play an important role in 
achieving and maintaining the post-mitotic state. The aberrant cell cycle entry observed in the 
CNS and the PNS of the Rb'^' embryo caused elevated levels of apoptosis. This again implied 
a role for pRb in protecting cells from apoptosis. Indeed, Rb'^~\E2F^~ mice showed reduced 
levels of ectopic cell cycle entry and apoptosis in both the CNS and the lens at 13.5 d.p.c. as 
compared to Rb'^' embryos, suggesting that these defects are in part due to de-regulated E2F-1
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activity. However, this mechanism is tissue type-specific, as loss of E2F-1 has less of an 
effect on cell cycle entry and apoptosis in the PNS.
It is clear that pRb interacts with other non-E2F targets. This was best demonstrated 
in the analysis of pRb mutants that showed reduced affinity binding to E2Fs, but were still 
capable of augmenting MyoD transcriptional activity and inducing tissue-specific gene 
transcription (142). Furthermore, these mutants retained certain tumour suppressor functions. 
Therefore, at least part of the tumour suppression function of pRb correlates with its ability to 
promote tissue differentiation.
Although the pRb protein level does not change dramatically upon differentiation, 
pRb was found to be hypophosphorylated during cell cycle exit. Hypophosphorylated pRb 
augments the transcriptional activity of various transcription factors important for tissue 
differentiation, including MyoD for myogenesis and C/EBPa for adipogenesis (27, 57). Also, 
pRb was shown to bind to C/EBPa (27), NF-IL6 (28) and AP-1 (126) transcription factors, 
and enhance their DNA binding activity.
Other targets of pRb
Low-penetrance pRb mutants, such as substitution of tryptophan (W) for arginine (R) 
661 in the B pocket of pRb (661W), which are inactivate in both E2F and LXCXE binding, 
still retain tumour suppressor activity. In cell based assays, the 66IW mutant was shown to 
inhibit Gl/S progression. Furthermore, C pocket mutations in full-length pRb also reduced 
pRb function (180). Taken together, these suggest that non-E2F targets of pRb contribute to 
tumour suppression.
The C-terminus of pRb interacts with the c-Abl tyrosine kinase (176, reviewed in 
174). The c-Abl kinase is ubiquitously expressed in both the cytoplasm and nucleus. The
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nuclear kinase activity of c-Abl is under cell cycle control, being activated during cell cycle 
progression. Interestingly, c-Abl can simultaneously interact with pRb when the pocket 
region is occupied by E2F.
The human homologue of yeast SNF/SWI2 proteins, hBrm/hBrg interact with pRb in 
a pocket-dependent manner (166, reviewed in 18). hBrm/hBrg has chromatin remodelling 
activity and co-operates with pRb in the transcriptional activation of the GR (151). Together 
with the observation that pRb also recruits HDACs, it suggests that pRb regulates 
transcription via chromatin remodelling mechanisms.
pRb interacts directly with the largest TATA-binding protein associated factor, 
TAFii250, through multiple regions in each protein (143, 144). Apart from being part of the 
basal transcriptional machinery, TAFn250 possesses intrinsic HAT activity and kinase 
activity. Mutagenesis studies suggested that TAFn250 is a cell cycle regulated protein and its 
HAT activity is required for cell cycle progression (41). pRb inhibited the kinase activity of 
TAFii250, but was not found to be acetylated by TAFn250 (150). These findings point to an 
additional mechanism for pRb regulation of transcription by modulating the activity of the 
basal transcription apparatus.
Evidence also exists that pRb modulates transcription mediated by RNA polymerase 
I and III (reviewed in 179). During differentiation of U937 myeloid porgenitor cells, pRb 
becomes localised to nucleoli, which are the major sites of ribosomal gene transcription by 
RNA polymerase I. Immunoprécipitation experiments demonstrated that pRb can associate 
with transcription factor UBFl, and that this interaction compromised the transcriptional 
activity of UBFl, thus leading to the down-regulation of Pol I transcription (24).
Loss of pRb function also correlated with up-regulation of Pol III transcription in 
tumour cells. fibroblasts have elevated Pol III activity compared to Rb^^^ fibroblasts.
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Immunoprécipitation and co-fractionation experiments demonstrated that pRb interacts with 
TFIIIB, and TFIIIB was identified as a target of repression by pRb (90).
Summary of pRb function
The pRb tumour suppressor protein is an essential component of the cell cycle clock, 
integrating both positive and negative signals for cellular growth and proliferation with the 
transcription machinery. The pRb protein exerts its tumour suppression function by both 
antagonising and synergising with downstream effectors, such as E2F. pRb has two modes of 
action: it can inactivate E2F transcription activity, and assemble active repression complexes 
with E2F. Apart from E2F, pRb synergies with various factors to promote cellular 
differentiation. The differentiation property of pRb contributes partly to its tumour suppressor 
function. The pRb-c-Abl interaction and pRb-MDM2 interaction also add to its growth 
suppression ability, though the mechanisms remain to be elucidated.
It is also clear that pRb is a master regulator for transcription. It can both activate and 
repress transcription in a context-dependent manner. pRb interacts directly with HAT, 
HDACs, and hBrm/hBrg, all of which are classes of proteins involved in chromatin 
remodelling. It will be important to investigate how pRb regulates transcription in a 
chromatin environment. Last but not the least, pRb regulates transcription by Pol I, II and III, 
thereby integrating the cell cycle clock with the biosynthetic capacity of the cell in 
controlling cellular proliferation and cellular growth.
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P300/CBP
The p300/CBP proteins are a family of transcription co-activators which mediate 
multiple, signal-dependent transcription events (reviewed in 75, 145)'. They participate in many 
cellular programmes, including proliferation, differentiation and apoptosis (reviewed in 52). 
Most of the studies on p300/CBP have focused on their ability to act as transcription co­
activators. For example, they have been considered as part of the basal transcription machinery 
(81), as they interact with TBP (140), TFIIB (48), TFIIE, TFIIF (68) and the RNA helicase A 
(124). It is believed that p300/CBP can bridge DNA-binding factors with the basal transcription 
machinery to allow transcriptional activation (reviewed in 52, 75). Secondly, p300/CBP 
possesses HAT activity (13, 128), which might act directly on nucleosomes to activate 
transcription via chromatin remodelling related mechanisms (reviewed in 21, 54, 60, 82, 170), or 
could act on transcription factors, such as p53 (56, 100, 139) and E2F-1 (110, 111), and/or other 
factors such as TFIIE, TFIIF (68) and HMG proteins (121) to regulate transcription. More 
recently, p300/CBP has been implicated in the regulation of protein stability (53, 110). Finally, a 
role for their involvement in tumour etiology has been established by the fact that they are 
targets of viral oncoproteins, including Ad E lA  (180, reviewed in 42, 118) and SV40 LT (45). 
Mutations in p300 and cbp were also found in colorectal tumours, Rubinstein-Taybi Syndrome 
(RTS), leukaemia and epithelial malignancies (reviewed in 51). Therefore, p300/CBP may 
function as classical tumour suppressors.
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The p300/CBP protein family
The paralogous proteins p300 and CBP were originally identified as binding proteins to 
E lA  and the cAMP response element binding protein (CREB) respectively (31, 45, 182). Their 
genes are conserved in a variety of multicellular organisms from worms to humans. A number of 
conserved sequences were present between the two proteins, which comprise of most of the 
known functional domains in p300/CBP (6). These include: i) the bromodomain, which is 
conserved among many mammalian HATs; ii) three cysteine-histidine rich domains, also known 
as the CHI, CH2 and CH3 domain; iii) a KIX domain; and iv) an ADA2 domain, which shows 
extensive homology to a yeast transcription co-activator ADA2 (Fig 1.5). The CHI, CH3 and the 
KIX domains are important in mediating protein-protein interaction. A number of cellular and 
viral proteins bind to these regions (reviewed in 147). Crystallographic structural studies on the 
bromodomains of pCAF (39) and TAFn250 (74) suggested that this region performs a unique 
function in recognising acetylated peptides. Given that many cellular factors are found to be 
acetylated by p300/CBP (see later), the bromodomain could function to recognise specific 
motif(s) which are acetylated. In addition, different combinations of bromodomains might 
recognise different patterns of acetylated nucleosomes. Both the N- and the C-terminal regions 
of p300/CBP possess /ranractivation functions, though the mechanism is not clear. The HAT 
activity resides within the central region of the protein (128). It is likely that the modular 
organisation of p300/CBP proteins is a crucial feature that allows them to function as a scaffold 
in the formation of multimeric transcription co-activator complexes. The p300/CBP protein 
family also contains at least two other putative members, p270 and p400, which have not yet 
been fully characterized (51). The p270 protein shares some common antigenic determinants 
with p300, and was found to be a component of the mammalian SWI/SNF complex (34).
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Although p300 and CBP share extensive homology, genetic and molecular analyses 
suggested that they perform both overlapping and unique functions. In transient transfection, 
most transcription factors were activated by either p300 or CBP (reviewed in 52, 75, 147). 
Similarly, E lA  binds to CBP and CREB can use p300 for co-activation (5, 102). The p300'^\ 
cbp'^' and compound p300/cbp heterozygous mice show similar phenotypes in embryonic 
lethality, defects in growth and in neural tube closure, suggesting certain overlapping functions 
between p300 and CBP during embryonic development (189). Furthermore, some p300 and cbp 
heterozygous mice suffered early lethality. One explanation is that there is an absolute 
requirement for p300 and cbp gene activity during early embryogenesis to cany out certain 
functions, and a slight drop of, for example, 0.25-fold in the total p300/CBP protein levels may 
leave embryoinc development unviable. Consistently, RTS, which is a haplo-insufficient 
syndrome where patients are heterozygous for mutations in the cbp allele, suggests that the loss 
of one functional copy of cbp gene is sufficient to confer a propensity for malignancy (129). 
Indeed, cbp heterozygous mice also show skeletal abnormalities reminiscent of RTS (158). An 
alternative but non-exclusive model that could also accommodate the above observations 
suggests that p300 and CBP have unique cellular functions. To this end, the p300~ '^ fibroblast 
was found to have specific defects in retinoic acid-dependent transcription, whilst retaining 
normal CREB function (189). Furthermore, the heterozygous cbp mice showed highly penetrant, 
multilineage defects in haematopoietic differentiation (89). These mice had an increased chance 
of developing haematologic malignancies at advancing age. This pathology was unique to the 
cbp'^ '^ ' mouse, but not in the p300^^' mouse, indicating that a full complement of cbp, but not 
p300, is required for noraial haematopoietic differentiation. Furthermore, using hammerhead 
ribozyme technology to specifically inactivate either p300 or CBP, it was demonstrated that the 
retinoic acid-induced differentiation of F9 embryonal carcinoma cells was inhibited by co­
expression of a p300-inactivating ribozyme, but not a CBP-inactivating ribozyme (77).
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Similarly, ionizing radiation (IR)-induced apoptosis was found to be impaired in p300-deficient 
cells, but not in CBP-deficient cells (193). Interestingly, ribozymes directed against either p300 
or CBP can block retinoic acid-induced apoptosis of F9 cells (77). Overall, it suggests that p300 
and CBP have overlapping functions, but they also perform unique tasks in certain biological 
programmes.
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Figure 1.5 Schematic representation o f p300/CBP.
a) Alignment of p300 and CBP protein. The shaded regions indicate areas of high homology, 
and percentage of identity between the two proteins are indicated.
b) The diagram shows various functional domains in p300, including three cysteine/histidine- 
rich domains, C/Hl, 2 and 3 respectively, a KIX domain, and the bromodomain. Both the N- 
and C-terminal regions of p300/CBP have framactivation function. The HAT activity maps 
to the central region of the protein. The regions in p300/CBP that binds to target proteins are 
indicated.
23
Transcription regulation by p300/CBP
p300/CBP are versatile transcriptional integrators which have at least thiee different 
modes of regulating transcription. Here, I describe each mode in detail,
i) A bridge to the transcriptional machinery.
The initiation of transcription by RNA polymerase II requires sequence-specific 
transcription factors to bind to the promoter and/or enhancer elements, and the basal 
transcription machinery which physically caiTy out the transcriptional function. Unless 
the transcription factors can directly interact with the basal transcription machinery, 
bridging proteins are required to establish the contact between these two sets of proteins. 
p300/CBP is known to bind to a variety of transcription factors (reviewed in 75, 147), 
and interact directly with various components of the transcriptional machinery, 
including TBP, TFIIB, TFIIE and TFIIF (48, 68, 140). Therefore, in the simplest view, 
p300/CBP functions as a ‘bridge’ to connect transcription factors with the basal 
transcription machinery. An important feature of this mechanism is how the ‘bridge’ can 
be regulated, thereby providing specificity to the transcriptional regulation. The analysis 
of pSOO^ "'' and cbp'^ '^ mice suggested that there is a limiting amount of p300/CBP 
proteins under physiological conditions, as various levels of embryonic lethality were 
observed in the heterozygous mice (189). In keeping with these observations, over­
expression experiments suggested that transcriptional repression among certain 
transcription factors can also be mediated through p300/CBP (reviewed in 147). Since 
the number of signal transduction pathways which require the activity of p300/CBP is so 
large, Rosenfeld and colleagues (76) proposed that a co-ordinated re-distribution of 
p300/CBP activity among different classes of factors in a signal-dependent manner 
would allow the specificity of transcriptional regulation (76, 163). For example, the
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engagement of p300/CBP by certain hormone receptors was shown to inhibit AP-1 
transcription (76). Over-expression of E2F-1 can block p53 fm^jactivation in a 
p300/CBP dependent manner (92). Similarly, over-expression of p53 represses TRE- 
regulated promoters and such inhibition relies on the physical interaction between p53 
and p300 (8). Furthermore, agonists of the Ras pathway can inactivate cAMP-responsive 
genes, specifically interfering with CREB-dependent transcription (125). A plausible 
mechanism for these results suggests that the activation of the Ras pathway promotes 
p300/CBP association with mitogen-regulated S6 kinase pp90^*’^. The physical 
interaction of pp90*^ ®*‘ with p300/CBP may be sufficient to compete off CREB- 
dependent transcription since a catalytically inactive pp90^®  ^ can still block CREB 
function (125). Last but not the least, binding of E lA  to p300/CBP inactivates a number 
of cellular and viral promoters and enhancers (147, 155). For example, the expression of 
genes induced by muscle differentiation is inhibited by E lA  (132, 133). E lA  also 
antagonises SV40 and polyoma virus enhancers in a p300/CBP dependent manner (147, 
155). Taken together, these findings suggest that p300/CBP is a focal point whereby 
different signal transduction pathways compete for a limited pool of these promiscuous 
activators, thereby targeting their specificity towards certain promoters. Viral 
oncoporteins, such as Ad E lA  and SY40 LT, sequester p300/CBP activity, thereby 
suppressing differentiation in favour to retain cells in an active proliferative state.
ii) An assembly platform for multi-protein complex formation.
The p300/CBP proteins act to nucleate the assembly of diverse co-factor 
proteins into co-activator complexes (87, 178, 184). Moreover, p300/CBP has been 
frequently found in complex with other HATs, including pCAF (188), SRC-1 (154), and 
P/CIP/ACTR/AIBI (26). By providing an assembly platform for transcription factors.
25
other HATs and components of the basal transcriptional machinery, they might increase 
the relative concentration of these factors in a local environment to facilitate protein- 
protein and protein-DNA interaction. Maniatis and colleagues (81) have proposed an 
enhanceosome concept which can explain the specificity of transcription regulation 
mediated by p300/CBP (23, 81). The current view is that in order for a cell to use a 
limited repertoire of activators or co-activators in response to diverse regulatory cues, 
co-operativity and transcriptional synergy are employed where a small combination of 
ubiquitous, signal- and tissue- specific activators can define an exponentially large 
number of regulatory decisions. Studies on the human interferon (IFNP) enhancer 
suggested that the surface of p300/CBP provides an assembly platform for different 
components of the transcription apparatus (81, 121). The recruitment of p300/CBP, 
together with transcription factors, such as ATF2/c-Jun, p50/p65 of NF-KB, and 
interferon regulatory factor 1, and architectural proteins such as high mobility group 
proteins (HMG), would determine the exact three-dimensional positioning of these 
multiple binding sites, which is important for co-operativity. Subsequently, it was 
shown that both p300/CBP and the p300- associated factor pCAF are required for the 
activation of transcription from the IFN(3 enhanceosome (121). Interestingly, p300/CBP 
and pCAF were found to acetylate the HMG protein in the enhanceosome, and the 
acétylation of HMG I by p300/CBP also leads to the destabilization and disassembly of 
the enhanceosome, which is important in turning off IFNp gene expression (121).
Since many of these multi-protein complexes also contain multiple HATs, it is a 
surprise at first if they only acetylate nucleosomes. One possible scenario is that 
transcription factors need to recruit multiple HATs in order to achieve a critical mass of 
enzymatic activity to overcome deacetylation on promoters. Subsequently, many non-
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chromosomal proteins were shown to be acetylated by p300/CBP and pCAF. This 
suggests that different HATs might have different substrate specificity, and the 
combination of active HATs is specific to each promoter in a context dependent manner. 
The three dimensional structure studies on the bromodomain, which is commonly found 
in many HATs identified so far, revealed its unique role in recognizing acetylated 
peptides (39, 74). The double bromodomain in TAFu250 binds to acetylated peptide 70 
times stronger than the pCAF bromodomain (74). The distance of the two binding 
pockets on TAFn250 is about seven amino acid residues apart, which fit well with sites 
of acétylation observed on H4 in vivo (74). Therefore, another possibility exists that the 
multiple HATs provide a combination of bromodomains in recognizing unique patterns 
of acetylated nucleosome in promoter regions. Furthermore the bromodomain may also 
mediate protein-protein and protein-nucleosome interactions. From the studies of the 
BFNP enhanceosome, it also indicated that different HATs might function at different 
stages during the transcription process. In this case, p300/CBP HAT activity is required 
to terminate IFNp gene expression, suggesting a complex scenario where HAT activity 
plays roles in both transcriptional activation and post-induction turnoff (121).
iii) Acetyiation-dependent transcription regulation
Acétylation of multiple sites in the core histone tails is known to be associated 
with transcriptional activity; hypo-acetylation is generally correlated with transcriptional 
repression and hyper-acetylation is correlated with transciptional activation (reviewed in 
21, 54, 60, 170). It was thought that the neutralization of positive charge on histone tails 
by acétylation might weaken the histone/DNA interaction, thereby facilitating RNA 
polymerase II and its associated factor to access the DNA template. Crystallographic
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studies on the nucleosome structure further indicated that the histone tail was involved 
in maintaining higher order chromatin structure, and acétylation might relieve chromatin 
structure to a more ‘open’ state for transcriptional activation (104). When p300/CBP 
was found to possess HAT activity, it was immediately assumed that the intrinsic HAT 
activity was important for its co-activation function. In vitro, p300/CBP can acetylate all 
four core histones, with preference toward H3 and H4 (12, 128). By tethering the 
p300/CBP HAT domain to the Gal4- DNA binding domain, it was shown that the HAT 
activity is required to stimulate transcription from the adenovirus major late (AdML) 
and E4 promoters, but not ElB or the SV40 promoters (109). This demonstrated the 
promoter selectivity of the HATs. Mutations which abolish HAT function also correlate 
with loss of stimulation from the AdML and E4 promoters (109). These studies provided 
evidence that the HAT activity is required for the transcriptional activation. However, it 
is yet to be established that if the HAT activity acts on nucleosomes, and participitates in 
chromatin remodelling-related mechanisms. Furthermore, acétylation of specific lysine 
residues on histone tail (such as K8 and K16 on H4, and K9 and K14 on H3) appear to 
be most important for transcriptional regulation (21, 54). It is not clear what is the 
substrate specificity of p300/CBP HAT in vivo.
Abundant evidence also highlights the importance of non-chromosomal protein 
acétylation in regulating gene expression. A growing list of transcription factors, such as 
p53 (56, 100, 139), E2F (110, 111), c-Myb (160), MyoD (141), GATA-1 (17), EKLF 
(195) and HNF-4 (153), were found to be acetylated by p300/CBP and/or pCAF. In all 
cases, acétylation of these transcription factors was reported to enhance their DNA 
binding activity in gel shift assays. Acétylation neutralises the positive charge on the e- 
amino group of the lysine residues. This charge modification could cause 
conformational change, which seems to be a plausible explanation for the enhanced
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DNA binding activity observed for p53 (56). Alternatively, acétylation may create a 
motif which enhances protein-DNA recognition. This mechanism seems to 
accommodate well with the observation that so many transcription factors have been 
independently reported to have enhanced DNA binding activity upon acétylation. HTV- 
Tat is another substrate acetylated by p300/CBP and pCAF (78). Acétylation of Tat 
synergies with its transcriptional activation of the HIV-1 LTR (78). In this case, 
acetylated Tat was also found to promote its dissociation from TAR RNA, and enhanced 
its binding to the Tat-associated kinase, CDK9/P-TEFb. One example exists whereby 
acétylation inhibits transcription. Acétylation of dCTF inhibited its binding to 
Armadillo, thereby leading to down-regulation of transcription (172). The basal 
transcription factors, TFIIE and TFIIF, were reported to be acetylated by p300/CBP 
(68). The consequence of this modification on basal transcription machinery function 
has not been explored. Overall, evidences suggested that nucleosome and protein 
acétylation are both relevant towards p300/CBP-dependent transcriptional regulation.
Regulation of cell cycle by p300/CBP.
The fact that p300/CBP are specific targets of E lA  immediately suggested their 
potential importance in cell cycle regulation (182, 185). Detailed studies on the interaction 
between E lA  and p300/CBP support such a role in inducing cellulai" DNA synthesis and S phase 
progression (155). Furthermore, E lA  mutants deficient in binding to p300 are defective in 
transformation function (173). Direct evidence that p300/CBP are important in cell cycle 
regulation was demonstrated in the study of p300 and cbp knockout mice (189). p300/CBP are 
required in both cellular proliferation and differentiation. p300 nullizygous embryos start to die 
about E10.5, showing defects in neural tube closure and heart development. Specifically, defects
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in cardiac myocyte differentiation were thought to contribute to the early lethality in these 
homozygous mice. Consistently, cell-based assays indicated that p300/CBP collaborate with the 
MyoD family of proteins in modulating the expression of downstream myogenic factors such as 
myogenin and MEF2, and promote cell cycle withdrawal in myocytes induced to differentiate 
(132, 133, 141, 192). Furthermore, the p300/CBP interacting protein pCAF is also required for 
this myogenic program since micro-injection of either anti-p300/CBP or anti-pCAF antibodies 
block MyoD-dependent transcription in muscle cells. Whilst the p300 HAT domain was 
dispensable for MyoD transcription, mutation in the HAT domain of pCAF impairs Myo-D- 
dependent /ran^activation (141). cbp""^ ' mice showed defects in haematopoietic differentiation, 
which subsequently led to haematologic malignancies at an advanced age (89). In this case, the 
differentiation promoting properties of CBP contributes a tumour suppression function. 
Consistently, p300/CBP has been implicated in the differentiation of haematopoietic tissues, 
such as B cells (46). Strikingly, inactivating p300/CBP homologue cbp-1 gene in 
Caenorhabditis elegans was shown to block nearly all differentiation programs except neuronal 
differentiation, which is the default pathway (145); mesodermal, endodermal, and hypodermal 
cells were completely absent in most of the embryos. A plausible mechanism is that two C. 
elegans transcriptional activators SKN-1 and PAL-1 require p300/CBP to initiate differentiation. 
Interestingly, inactivation of components of the HDAC complexes, such as hda-1, rba-1 and 
rba-2, can rescue certain cbp-1 phenotypes (145). This provides indiiect evidences that 
p300/CBP HAT activity is required for differentiation, at least in C. elegans, to counteract the 
repressive role on differentiation imposed by HDACs. These findings established a role for 
p300/CBP in cellular differentiation, which could partially contribute to its tumour suppressive 
function.
While it makes good sense for viral oncoproteins such as E lA  to antagonise p300/CBP 
function, and thereby suppress cellular differentiation in favour of cellular proliferation, it is
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interesting to note that p300/CBP may also be required for cellular proliferation. p300'^' embryos 
are significantly smaller than their wild-type littermates, showing defects in cellular proliferation 
(189). p300'^' MEFs (mouse embryonic fibroblasts) grow more slowly compared to wild-type 
cells, with phenotypes reminiscent of senescence. Since binding of E lA  to p300 also correlates 
with ElA-induced DNA synthesis (155), it is possible that the ElA-p300 complex is an active 
complex in stimulating cellular growth and proliferation.
Analysis of the cbp-1 deficient embryos of C. elegans suggested that apoptotic pathways 
were not affected (145). However, cell based assays indicated that p300/CBP can be involved in 
apoptosis. Cells deficient in p300, but not in CBP, have impaired IR (ionizing radiation) 
sensitivity (193). Moreover, p300/CBP deficient cells were shown to be resistant toward retinoic 
acid induced apoptosis (77). Functional sequestration of p300/CBP activity via ElA, or with a 
dominant negative fragment of p300, blocks p53-dependent apoptosis (8, 97), suggesting that 
p300 is involved in p53-dependent apoptosis. In this case, contradicting evidence also exists that 
co-expression of p300 with p53 induces p53-mediated G1 aiTest, but prevents p53-dependent 
apoptosis in SAOS2 cells (92, 160). However, in those assays, p300 augmented E2F-1 
dependent apoptosis (92). An additional level of complexity arises when p300 was demonstrated 
to regulate p53 turnover (53). The N-terminal region of p300 can mediate a ternary complex 
between p300-p53-MDM2, which in turn controls p53 stability. The proto-oncogene MDM2 is 
important in regulating p53 stability, via a ubiquitin-dependent protein degradation pathway (53, 
101). MDM2 mutants capable of binding to p53, but deficient in binding to p300, fail to promote 
p53 degradation. Similarly, a short p300 fragment consisting of the p53 binding region in the N- 
terminus acts in a dominant negative fashion to enhance p53 stability (53). Therefore, p300 has a 
dual role in controlling p53 activity, both in augmenting p53 /ran^-activation function and 
promoting p53 degradation. This provides a possible explanation of the contradictory 
observations for p300 in regulating p53-mediated apoptosis. The exact experimental outcomes
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may very much depending on the cellular status, whether in favour of p300 in activating p53 
transcription, or in promoting p53 degradation. The p300/CBP-pCAF complex can arrest the cell 
cycle (188). This protein complex might regulate target gene expression which is crucial in 
controlling Gl/S transition, such as p21/WAFl (47). Over-expression of ElA, which 
antagonises pCAF binding to p300/CBP, drives cells into S phase (188). As discussed above, the 
p300/CBP-pCAF complex can co-operate with MyoD in myogenesis. Overall, p300/CBP 
proteins are involved in all cellular programmes, from differentiation, to proliferation and 
apoptosis. This leads on to the next question as to how p300/CBP are regulated in a timely 
manner to exert biological specificity.
Regulation of p300/CBP activities
p300/CBP are nuclear phosphoproteins (185). CBP, together with various factors known 
to be important regulators of the cell cycle and transcription, such as p53, pRb, Daxx, PML, 
BLM and SUMO-1, reside in a unique nuclear structure called the nuclear body (reviewed in 
198). At present, the biological significance of the nuclear body is not well understood and it is 
proposed that it is a depot for storage and titration of nuclear proteins. The phosphorylation 
status of p300/CBP is cell cycle regulated, being hyperphosphorylated at mitosis (185). p300 
isolated from undifferentiated F9 cells is unphosphorylated. It is then phosphorylated and 
becomes competent to activate transcription upon treatment with retinoic acid which induces 
differentiation (83). Viral oncoproteins, SV40 LT and ElA, bind to p300/CBP in the same 
region, but have a different effect on p300/CBP phosphorylation status (11, 45). T antigen co- 
immunoprecipitates with the hypophosphorylated p300, and suppresses p300/CBP 
phosphorylation (45). In contrast, E lA  simulates p300/CBP phosphorylation, probably via 
cyclin/CDKs (45). Cyclin-dependent kinases, Cdk2 and Cdc2 (11) have been found to 
phosphorylate p300 in vitro. p300 is required for the induction of p53-independent p21 gene
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expression, which is an inhibitor of CDK activity. Therefore differentiation can also be 
associated with hypo-phosphorylated p300 (114). The C-terminal region of p300/CBP interacts 
with cyclin E-Cdk2, as well as TFIIB and ElA. 12S ElA, which is an inhibitor of p300- 
dependent transcription, does not affect p300 association with cyclin E-Cdk2 (48). However, 
13S ElA, which is also a pleiotropic transcription activator, enhances p300/cyclin E-cdk2 
association (48).
p300/CBP can also be phosphorylated by other kinases in response to various upstream 
signals. For example, CBP is phosphorylated by MAPKs (mitogen-activated protein kinases) or 
PKA (protein kinase A), both of which enhance CBP rrani'activation potential (75). The 
bromodomain of GCN5 was reported to be phosphorylated by the DNA-PK family of kinases, 
which repressed GCN5 HAT activity (14). It is possible that the p300/CBP bromodomain might 
be similarly regulated by DNA-dependent protein kinases.
An important question regarding p300/CBP function is how its HAT activity is 
controlled during the cell cycle. Ait-Si-Ali et al (2) showed that HAT activity peaks at Gl/S 
transition. Furthermore, phosporylation of p300/CBP by cyclin E-cdk2 complexes in the C- 
terminal region of the protein stimulated the FL\T activity (2). In the same study, E lA  was also 
demonstrated to activate the HAT activity (2). These observations suggest that the HAT activity 
drives cell cycle progression, and that viral oncoproteins might mimic proliferative signals to 
activate p300/CBP HAT activity. Similarly, E lA  was shown to immunoprecipitate HAT active 
fractions of p300/CBP and pCAF (12). However, this scenario is challenged by several reports 
indicating that E lA  inhibits p300/CBP and pCAF HAT activity in vitro (25, 58). Furthermore, 
p53 acétylation is also inhibited in the presence of E lA  (25). Results from various laboratories 
have indicated that E lA ’s effect on histone acétylation is concentration dependent; at a low 
level, it enhances histone acétylation, whereas at a high level, it represses histone acétylation. 
The physiological relevance of these observations is not clear. However, one noticeable feature
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is that E lA  does not inhibit the intrinsic HAT activity of p300/CBP. E lA  was acetylated in those 
in vitro assays, and p300/CBP was auto-acetylated. Given p300/CBP proteins are consistently 
found in complex with other HATs, it is possible that other HATs, such as pCAF or SRC-1, 
might acetylate p300/CBP as a substrate. How acétylation controls p300/CBP function awaits 
further investigation.
p300/CBP in human diseases.
Accumulating evidence has demonstrated that mutations in p300 and cbp genes are 
linked to the onset of a number of human tumours, suggesting that p300/CBP may function as 
classical tumour suppressors (reviewed in 51). This is consistent with the early working model 
that viral oncoproteins, such as E lA  and SV40 LT, target and antagonize p300/CBP tumour 
suppression functions. Mutations in cbp were first described in RTS patients, which is an 
autosomal-dominant disease characterized by mental retardation, skeletal abnormalities and high 
incidence of neoplasia (129). Most of the RTS patients are heterozygous for the mutation, 
suggesting a full complement of cbp gene dosage is crucial for normal development. 
Consistently, cbp'^ '^ mice showed skeletal abnormalities reminiscent of RTS patients (158). As 
discussed above, cbp'^ '^ mice have defects in haematopoietic differentiation, which subsequently 
leads to haematologic malignancies at advanced age, providing direct evidence that CBP 
functions as tumour suppressor (89). Furthermore, bi-allelic inactivating somatic mutations in 
the p300 gene have been observed in gastric, colon and breast cancers (50, 122). Various p300 
mutations leading to truncated proteins were detected in primary tumours and tumour cell lines 
(50). In many cases, the somatic mutations are associated with loss of heterozygosity (LOH) of 
the second allele. These observations are consistent with Knudson’ hypothesis that p300 behaves 
as a classical tumour suppressor gene.
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The p300/cbp genes are also found in various translocation events, and contribute to 
haematological malignancy probably through gain of function mutation. For example, MOZ- 
CBP fusion was reported in one AML (acute myeloid leukemia) patient (16). The MOZ gene 
encodes a putative HAT based on it homology to a yeast HAT, SAS2. The hybrid protein 
consists of 5’-MOZ/CBP-3’ and retains the HAT domains from both proteins. Similaily, a 
second translocation of the cbp gene to the MLL gene (mixed lineage leukemia) was observed in 
chronic myeloid leukemia and myelodysplastic syndrome (152). Most of these translocations 
arise as a consequence of anti-cancer treatments. In another case, one patient suffering from 
therapy-related AML was identified as having an in-frame fusion of MLL with p300 gene (67). 
Since both MOZ and MLL have been implicated in chromatin remodeling functions, these fused 
proteins may cause aberrant and deregulated gene expression to prevent proper differentiation 
and cell cycle control. Whilst the p300/CBP tumour suppression function is not well understood, 
the fact that they interact with both p53 (55, 92, 97) and pRb/E2F (92, 164) pathways may 
provide clues as to the underlying mechanism. As demonstrated by Lee et. al. (92), the ability of 
p300 to augment p53 mediated growth arrest, and E2F-1 dependent apoptosis may be one 
explanation to its tumor suppressive function.
Discussion
It has becoming clear that p300/CBP aie versatile transcription co-activators, 
participating in many cellular processes. These inculde; 1) the formation of a physical bridge 
between transcription factors and the basal transcription machinery; 2) an intrinsic HAT activity, 
which regulates cellular and nucleosomal targets; 3) a scaffolding function for multi-protein 
complexes formation; 4) providing basic cellular functions, including DNA replication, cell 
growth, differentiation and apoptosis; 5) mediating cross-talk among different signal 
transduction pathways.
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Through studies on p300/CBP, a lot has been learned about transcriptional regulation 
and cell cycle regulation. However, many questions relating to p300/CBP function remain to be 
answered. For example, there are uncharacterised members of the p300/CBP family, and it will 
be interesting to establish how therr properties differ from each other. Secondly, the regulation of 
p300/CBP protein function is relatively unexplored at present. It is known that p300/CBP can be 
phosphorylated and acetylated. CBP co-localizes with PML proteins in nuclear bodies, which are 
discrete nuclear structures that contain other proteins known to carry key function in cell cycle 
regulation, transcription and translation control. Curiously, SUMO-1, which performs another 
kind of post-translational modification called SUMOylation by attaching a ubiquitin-like protein 
SUMO to the lysine residues, is also localised in the nuclear bodies (198). It is possible that 
p300/CBP can be SUMOylated, in common with various other proteins in the nuclear body. 
How the p300/CBP family protein activity is modulated at the post-translational level requires 
further investigation.
Although the intrinsic HAT activity of p300/CBP is undoubtedly involved in 
transcriptional control, its physiological substrates are unclear. Furthermore, it is not known 
whether p300/CBP HAT activity acts only on nucleosomes. The picture is much more 
complicated as many transcription factors, and non-chromosomal proteins, were found to be 
acetylated by p300/CBP in vitro. Protein acétylation could be a much more common event than 
previously thought, and contribute in many aspects of cellular function apait from transcription. 
In this case, evidence does exist that acétylation might also regulate nuclear transport (13). 
Genetic and biochemical analysis suggests that p300/CBP are classical tumour suppressors, 
although the underlying molecular mechanisms are still poorly understood. The HAT activity 
appears to contribute to their tumour suppressive function, as p53 acétylation was shown to be 
induced under certain DNA damaging conditions (139). Moreover, genetic analysis supports a
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role for the HAT activity in promoting cellular differentiation, which may also indirectly 
contribute to the tumour suppressive effect.
An intriguing report indicates that p300 is involved in controlling p53 stability together 
with MDM2 (53). This observation will surely lead to many more investigations on the 
functional interaction between p300/CBP and the ubiquitin-dependent protein degradation 
system, which is important in cell cycle control. Further experiments will be required to 
substantiate this finding. Since both acétylation and ubiquintination occurr on lysine residues, it 
is possible that the HAT activity also plays a role in regulating protein stability.
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Chapter 2: Materials and Methods
Plasmids
pGEX-Rb and A21&A22 mutants have been described in Bandara et. a l, 1991 (10). 
pGEX-Rb 763-928, pCDNA3-9E10Rb, pGEX-107, pGEX-p53 were kind gifts from Robert 
White and Sybille Mittnacht. pGEX-Rb 794-829, 844, 857, 864, 876, 884, 896, 910 (1) were 
kindly provided by Peter Adams. pGEX-Rb 830-884, 830-928, 881-928, 792-928, 702-766, and 
641-775 were cloned by direct PGR (for primers, see table 2.1) from pCDNA3-9E10-Rb. pGEX- 
Rb 379-656 was cloned by restriction digest using Nhel and EcoRI from pGEX-Rb 379-928. 
pGEX-ElA (12S), AN36, pm928, were cloned by PGR (for primers, see table 2.1) from pCMV- 
E lA  or pCMV-ElA pm928 constructs (88). pGEX-E 1AACR1 and E1AACR2 were cloned by 
PGR (for primers, see table 2.1) from Sp 53 and Sp CS (9). The PCR products were cloned 
directly into pGEX-KG vector (Pharmacia). His-p300'"'"", Flag-p300‘^^ '^^ ^^ '^  bacterial 
expression vectors and Flag-300 (FL) baculovirus were kind gifts from Nakatani (128, 188). 
Mammalian expression vectors for MDM2, cyclin E, and CDK2 also have been described (101, 
119). Flag-HDAC was a gift from Linda Smith. 3X-E2F (lue) and 3x-E2Fmut (lue) were gifts 
from Lan Bandara. pGEX-cyclin D was a gift from Rene Bernards. pGEX-E7 was a gift from 
Kate Moore. TAFn250 baculovirus was a kind gift from Peter Verrijzer. pG4-p53, pG4-E2F-l, 
pHA-E2F-l, pCMV-(3gal, pVP-16, pG 4-p300'" '''\ and pG4-p300'''''''" plasmids have been 
described in Lee et. al. (92). pG4-AdML(luc) reporter was cloned from pG4-AdML(CAT) 
reporter into pGL13-luc backbone (France et. ah, personal communication). pGEX-p300’’^®^ and 
pGEX-p300'™-‘'”  ^were gifts from Richard Eckner (45). The pHA-NAP-2'"\ and
were generated by direct PCR from pHA-NAP-2 (for primers, see table 2.1). The PCR products 
were cloned into the pCDNA3-HA vector using BamHl/XhoI restriction enzymes. pHA-NAP-2,
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pHA-NAP-2"°''\ pHA-NAP-2^"°’^ '“, His-NAP-2 and pVP16-NAP-2 plasmids were cloned using 
standard procedure (Shikama et. a l, in press). For the construction of various pGEX-p300 
constructs, the appropriate fragments were re-cloned from pG4-p300 constucts which were 
described in Lee et. al (92). In short, pG4-p300‘*‘®'™‘’ was cloned by PvuII digestion from the 
pG4-p300‘^ ’^  backone. The insert was cloned into the Xhol/Bglll sites of the pG4 backbone. 
pG4-p300^^“ ’^ ®^‘ was cloned using BstEII and Bglll digestion from the pG4-p300‘^ ’ '^^ ®^‘* backbone. 
To generate pGEX-p300'^“ ‘”\  pG4-p300®'‘‘^ ®^'‘ was cut by Xbal and Eco47III, and the fragment 
was cloned into the XhoI(blunt)/XbaI sites of the pGEX-KG. To generate pGEX-p300"^^ '^ \^ the 
fragment was cut out from pG4-p300^“‘'^ ®^‘ using EcoRI and Notl (blunt), and cloned into the 
Xhol (blunt)/EcoRI sites of the pGEX-KG backbone. pGEX-p300'^’^  ’^ '“ was cloned by cutting 
the fragment using Xhol (blunt)/SacI from pG4-p300^"^ '^°\ and cloned into the SmaFSacI sites 
of pGEX-KG. pGEX-p300’*’^ '^ “®“ was cloned by cutting the fragment from pG4-p300‘®’®'^ “®'’ using 
Clal (blunt)/SacI, and cloned directly into the Xbal (blunt)/SacI sites of the pGEX-KG. pGEX- 
p30oi906-2284 cloned by cutting the insert out from pG4-p300‘”“‘^‘^ ®^* using Xhol (blunt)/SacI, 
and cloned into the SmaFSacI sites of the pGEX-KG.
Plasmids 5’-primer 3’-primer
GST-Rb (830-884) 5 ’-cgggatccagaatcttagtatcaattgg-3 ’ 5 ’ -cggaattctcattcatctgatccttcaatatc-3 ’
GST-Rb (830-928) 5 ’-cgggatccagaatcttagtatcaattgg-3 ’ 5 ’ -cggaattctcatttctcttccttgtttg-3 ’
GST-Rb (881-928) 5 ’-cgggatccggatcagatgaagcagatg-3’ 5 ’ -cggaattctcatttctcttccttgtttg-3 ’
GST-Rb (792-928) 5 ’-cgggatcccctagttcacccttacgg-3’ 5 ’ -cggaattctcatttctcttccttgtttg-3 ’
GST-Rb (641-775) 5 ’ -ccgggattccattgaaatctacctctc-3 ’ 5 ’ -tcacctggtggaagcatactgc-3 ’
GST-Rb (702-766) 5 ’ -cgggatcccaaattatgatgtgttccatg-3 ’ 5 ’ -ccctcgagtcaaatatttgttttcagtctctg-3 ’
GST-E1A12S 5 ' -cgggatccatgagacatattatctgccac-3 ’ 5 ’-ccctcgagttatggcctggggcgtttac-3’
GST-ElA(pm928) 5 ’-cgggatccatgagacatattatctgccac-3 ’ 5 ’ -ccctc gagttatggcctggggc gtttac- 3 ’
GST-E1ACAN36) 5 ’-cgggatcccattttgaaccacctacc-3 ’ 5 ’ -ccctc gagttatggcctggggc gtttac- 3 ’
GST-EIACACRI) 5 ’ -cgggatccatgagacatattatctgccac-3 ’ 5 ’-ccctcgagttatggcctggggcgtttac-3 ’
GST-ElAfACR2) 5 ’ -cgggatccatgagacatattatctgccac-3 ’ 5 ’ -ccctcgagttatggcctggggcgtttac-3 ’
NAP2(1-123) 5 ’ -cgggatccatggcagaaaacagtctt-3 ’ 5 ’ -ccactcgagctaccacgctgactctgc-3 ’
NAP2(98-386) 5 ’ -cgggatccttgtaccagcctcta-3 ’ 5 ’-ccgctcgagtctcactgctgcttgc-3’
NAP2( 1-279) 5 ’-cgggatccatggcagaaaacagtctt-3’ 5 ’-ccactcgagctaggttcgtacggtgcc-3’
NAP2(234-386) 5 ’-cgggatccgacccgttttcttttg-3 ’ 5 ’ -ccgctcgagtctcactgctgcttgc-3 ’
Table 2.1 Primers used for PCR cloning.
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Site-Directed Mutagenesis
pDNA3-9E10Rb point mutants were generated using the Quickchange site-directed 
mutagenesis kit (Stratagene). In short, primer pairs (one for the sense strand, and the other for 
the anti-sense strand) for specific mutants were synthesized (Genosys), see table 2.2 for the 
primers for each mutant. The mutation sequences were introduced into the middle of the 
primers, and the primers were designed to have a T^ approximately 78°C (Tm=81.5 -I- 
0.41 (%GC) -  675/(number of base pair of the primer) - % mismatch). PCR reactions were 
carried out to generate the mutant DNA sequences. Since some of the primers have strong 
secondary structure, some PCR reactions were cairied out with modification. For example, in 
some reactions, 10% glycerol was added to the reaction mixture to relax the primer secondary 
structure. In other cases, first the sense and the anti-sense primers were used in independent PCR 
reactions for 3 cycles, then the two halves of the PCR reaction mixtures were mixed for another 
16 cycles. Using this method gave better product yield. The parental DNA, which was isolated 
from E.coli and contained méthylation modification, was digested away using Dpnl restriction 
enzyme. The restriction digest mixtures were used to transform XL 1-Blue supercompetent cells. 
The cloning strategy was such that by introducing the specific mutations, it would either create 
new restriction site(s), or destroy certain existing restriction site(s). The first screening was 
therefore carried out using restriction digest. 2-4 of the positive clones were then selected for 
DNA sequencing to confirm the correct mutants were made. All DNA sequencing was carried 
out by MWG Biotech. The DNA sequencing covered approximately the last 350 amino acids of 
the pRb sequences. In order to eliminate possible mutations elsewhere due to PCR, the mutant 
sequences were re-cloned into the wild-type backbone of pCDN-3-9E lORb using NheFXhoI 
digest. Generation of pGEX-Rb point mutants was done using Nhel/EcoRI digests from the
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respective pCDNA3-9E10-Rb mutant constructs. To generate the pG4-Rb and mutants, the 
EcoRI fragment from the pCDNA3-9E10-Rb or mutants were sub-cloned into the Xhol (blunt) 
of pG4mbackboneU77). All pG4-Rb constructs were from amino acid 300-928.
Plasmids Primer pair
713KA 5'-gtgttccatgtatggcatatgcgcagtgaagaatatagacc-3' 
5'-ggtctatattcttcactgcgcatatgccatacatggaacac-3'
713KR 5'-gtgttccatgtatggcatatgcagagtgaagaatatagacc-3' 
5'-ggtctatattcttcactctgcatatgccatacatggaacac-3'
765KA 5'-cggtcttcatgcagagactggcaacaaatattttgcagtatgc-3' 
5'-gcatactgcaaaatatttgttgccagtctctgcatgaagaccg-3'
765KR 5'-cggtcttcatgcagagactgcgcacaaatattttgcagtatgc-3' 
5'-gcatactgcaaaatatttgtgcgcagtctctgcatgaagaccg-3'
740KA 5'-gctgttcaggagacattcgcacgtgttttgatcaaagaagag-3' 
5'-ctcttctttgatcaaaacacgtgcgaatgtctcctgaacagc-3'
720,722KA 5'-gcagtgaagaatatagaccttgcattcgcaatcattgtaacagcatacaagg-3' 
5'-ccttgtatgctgttacaatgattgcgaatgcaaggtctatattcttcactgc-3'
729KA 5'-cattgtaacagcatacgcggatcttcctcatgctgttcag-3' 
5'-ctgaacagcatgaggaagatccgcgtatgctgttacaatg-3'
873,874RR 5'-ccctcctaaaccactgagaagactacgctttgatattgaag-3' 
5'-cttcaatatcaaagcgtagtcttctcagtggtttaggaggg-3'
873,874QQ 5'-caaccctcctaaaccactgcagcaactacgctttgatattgaag-3' 
5'-cttcaatatcaaagcgtagttgctgcagtggtttaggagggttg-3'
Table 2.2 Primers used for site-directed mutagenesis.
In vitro protein acétylation assay
PAGE analysis of protein acétylation was performed as described (128), with slight 
modification. Indicated amounts of input proteins were incubated at 30°C for 45-60 minutes in 
30pl volumes with 5X HAT assay buffer (250mM Tris pH 8.0, 25% glycerol, 0.5mM EDTA, 
250mM KCl, and lOmM sodium butyrate), 90pmol acetylate CoA (55 mCi/mol, Amersham 
Life Science Inc.) and appropriate amount of water. After incubation, reactions were stopped by 
adding 15|Li1 of 3X SDS loading buffer (150mM Tris-HCl (pH6.8), 6% SDS, 30% glycerol, 0.3%
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bromophenol blue, 3% mercaptoethanl), and analysed on SDS-PAGE. The gels were dried and 
exposed for autoradiography for 48-96 hours. Quantiation of protein acétylation level was done 
by phosphoimaging analysis typically after 16-24 hours of exposure.
For the filter scintillation assay, samples were prepared as described for in gel assay. 
Chicken histones used in the assay were purified and kindly provided by Linda Smith and 
William Cairns. After incubation, the reaction mixture was spotted onto Whatman P-81 
phosphocellulose filter paper and washed with 0.2M sodium carbonate buffer (pH 9.2) at room 
temperature 2-3 times, and once with acetone. The dried filters were counted in a liquid 
scintillation counter. The synthetic NAP peptides 141 (GDEEGEDEDDADVNPKK) and 142 
(NSLSDGGPADSVEAAKN), and the Rb peptide (see chapter 3) and the histone H4 peptide 
(SGRKGGKGLGKGGAKRHRK) were provided by Newcastle University.
Expression and Purification of Glutathione S-transferase Fusion Proteins
Glutathione S-transferase fusion protein expression and purifications were performed as 
described in the company protocol (Pharmacia). Fresh overnight cultures of BL21(DE3) pLys 
(Invitrogen) transformed with the appropriate pGEX-recombinants were diluted 1:10 in Luria- 
Bertani medium (LB) containing ampicillin (100|ig/ml) and incubated at 37°C with shaking. 
After 2 hours of growth at 37°C, isopropyl-P-D-thiogalactopyranoside (IPTG, Sigma) was added 
to final concentration of 0.5mM. The cultures were subsequently incubated at 30°C for 4-5 hours 
for protein expression before harvesting.
For fusion protein purification using glutathione-Sepharose (Pharmacia), bacterial 
cultures were pelleted by centrifugation at 6,000rpm for 10 minutes at 4‘^ C. The pellets were 
resuspended in cold PBS (Sigma, 5ml PBS/100ml of bacterial culture, PBS supplemented with 
protease inhibitors cocktail (Calibiochem)). The bacteria were then lysed on ice by mild 
sonication, and Triton-X-100 (Sigma) was added to the lysate to a final concentration of 1%.
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The lysate was incubated at 4°C for 30 minutes, then centrifuged at 13,000rpm, 4°C for 30 
minutes. The bacterial supernatants were rocked for 30-45 minutes at 4°C with glutathione- 
Sepharose (200p,l of beads/100ml culture). The glutathione-Sepharose beads were washed three 
times with 20ml of cold PBS supplemented with 1% Triton, and once with 20ml of cold PBS. 
For analysis of bound proteins, appropriate amounts of beads were boiled in IX sample buffer 
(50mM Tris-HCl (pH6.8), 2% SDS, 10% glycerol, 0.1% bromophenol blue, 1% 
mercaptoethanl), and loaded onto a SDS-polyacrylamide gel. Proteins were visualized by 
Coomassie blue staining. GST-fusion proteins were eluted in elution buffer (50mM Tris-HCl 
(pH8.0), lOmM reduced glutathioine, 120mM NaCl). All fusion proteins were subsequently 
dialysed into BClOO buffer (20mM Tris-HCl (pH8.0), 0.5mM EDTA, lOOmM KCl, 20% 
glycerol, 0.5mM DTT, 0.5mM PMSF).
Expression and Purification of His-tagged fusion proteins
The procedure for His-tagged fusion protein expression is similar to that described for 
GST-fusion protein expression. To purify His-tagged fusion protein, the procedure was adopted 
from the company instruction manual (Pharmacia). In short, 5ml of PBS (supplemented to final 
0.5M NaCl, lOmM imidazole pH7.4 and protease inhibitor cocktail (Calibiochem)) was used to 
resuspend bacterial pellets from 100ml cultures. The bacteria were then lysed on ice by mild 
sonication and pelleted at 13,000rpm for 30 minutes, at 4°C. The supernatant was collected and 
incubated with Ni-NBT agarose (QIAGEN) at 4°C for 1 hour. After incubation, the beads were 
washed 5 times in PBS (supplemented to final 0.5M NaCl, 40mM imidazole pH7.4). Elution 
was carried out using BClOO buffer supplemented with 200mM imidazole. His-EIA (13S) 
protein was a kind gift from Laurent Delavaine.
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Production of Fiag-p300 bacuiovirus
bacterial expression vector was a kind gift from Y. Nakatani. To 
generate the baculovirus of Flag-p300^^^^“^ '*^ '*, the BAC-To-BAC Baculovirus Expression system 
from Gibco Life Technologies was used. In short, Flag-p300^^ '^ '^ '^^ ‘^^ sequence was taken out 
from the bacterial expression vector by RsrII and Notl digestion. The fragment isolated was 
cloned directly into the RsrII and Notl sites of pFastBacHTa vector. After selecting the correct 
pFastBacHTa-Flag-p300^^^'^"^‘^ '^^  clones, the plasmid was transformed into Max Efficiency 
DHlOBac Cells, which contained Bacmid and helper plasmid. The colonies containing the 
recombinant bacmid showed white in colour, and recombinant bacmid DNA was isolated and 
used to transfect insect cells using CellFectin Reagent. Recombinant baculovirus containing 
Flag-p300^^^ '^ '^^ '^  ^was harvested 48 hour after transfection. The virus was amplified to a titre of 1 
X 10^  pfu/ml and used for infection for protein purification.
Expression and Purification of Fiag-p300 from sf9 ceiis
To express Flag-p300 proteins in sf9 cells, 1.5 x 10^  sf9 cells were infected with the 
appropriate baculovirus at a multiplicity of infection (M.O.I.) of 10. The sf9 cells were harvested 
for protein purification after 48 hours of incubation at 25°C. The method of purification was 
essentially described in Chen and Tjian, 1996 (29). The sf9 cells were pelleted by mild 
centrifugation at 700rpm, washed twice with cold PBS and lysed in 2ml of HEMG buffer 
(25mM Hepes-KOH (pH7.6), O.lmM EDTA, 12.5mM MgCE, 10% glycerol) supplemented with 
400mM KCl, 0.1% NP-40 and protease inhibitor cocktail (Calibiochem). The samples were 
quickly freeze-thawed three times and centrifuged at 13,000rpm, 4°C for 30 minutes. The 
supernatant was collected and incubated with anti-flag M2 affinity gel (Sigma, 200ul of 
beads/ml of supernatant) in HEMG buffer containing 200mM KCl. After 2 hours of incubation
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at 4°C, the beads were washed 5 times with HEMG buffer supplemented with 200mM KCl. 
Proteins bound on the beads were eluted in elution buffer which was composed of basically 
HEMG buffer supplemented with 160mM KCl and 1 mg/ml Flag-peptide (Sigma). Elution was 
carried out at 4°C for 2 hours. Proteins eluted were analysed by SDS-PAGE and visualized by 
Coomassie blue staining
Tissue Culture and Transfection
The C33A, U20S, SA0S2, T98G, HEK293, HeLa, and A31 cells were all cultured in 
Dulbecco modified Eagle medium (Gibco) supplemented with 10% fetal bovine serum at 37°C 
in 5% CO2. Sf9 cells for baculovirus production and protein expression were maintained in 
TCI00 medium (Gibco) supplemented with 5% fetal bovine serum at 25°C. The U20S cell line 
with the integrated reporter described in chapter 4 was a kind gift from Rene Bernards. HELA 
nuclear extracts were purchased from Computer Cell Culture. TSA were purchased from Sigma. 
Transfections were carried out using the calcium phosphate method as described in the Promega 
manual. For the mammalian two-hybrid assay, l|ag of the indicated pG4- plasmids were 
transfected with 0.5p,g of pVP16 or pVP16-NAP2 into U20S cells. Experiments were repeated 
in C33A cells. For the luciferase assay, cell extracts were prepared in reporter lysis buffer 
(25mM Tris-HjPO^ pH7.8, 2mM 1,2-diaminocyclohexane tetra acetic acid, 2mM DTT, 10% 
glycerol and 1% Triton X-100), and centrifuged at 13,000rpm at 4°C, 10 minutes. The 
supernatant was assayed for luciferase activity by mixing 300|Lil luciferase assay reagent (1:4, 
Promega) with 60pl cell extract and measuring the activity with a luminometer (Berthold 
Lumat). To measure p-galactosidase activity, lOOpl cell extract was mixed in lOOpl of 2X assay 
buffer (200mM Na phosphate buffer, pH7.3, 2mM MgCl^, lOOmM p-mercaptoethanol, 
1.33mg/ml ONPG (Sigma)). The reaction mixtures were incubated at 37°C until a reasonable
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yellow colour developed. The reaction was stopped by adding 500pl of 0.5M Na^COj to each 
sample, and the absorbance was measured at 420nm. The transcriptional activity of the reporter 
assay was normalised by luciferase activity/p-galactosidase activity. Immunoblotting was also 
carried out to confirm the expression of the transfected constructs. All reporter gene assays 
presented have been repeated at least 2-3 times to ensure the reproducibility of the result.
Western Blot and Immunoprécipitation
Anti-Ac-K antibody was purchased from New England Biolab. Anti-Ac-H4 antibody 
was purchased from Serotec. Anti-Rb antibody IF-8 was kind a gift from Julian Gannon. G3-245 
anti-Rb monoclonal antibody was purchased from Pharmingen and C-15 anti-Rb polyclonal 
antibody was purchased from Santa Cruz. E2F-1 antibody KH95 was purchased from Santa 
Cruz. Anti-MDM2 antibody H221 was purchased from Santa Cruz and Ab-1 monoclonal 
antibody was purchased from Calibiochem. Anti-Flag antibody (M2) was purchased from 
Sigma. Anti-p300 antibodies, C-20 and N-15 were purchased from Santa Cruz. Monoclonal anti- 
p300 antibody Ab-1 was purchased from Calibiochem. Anti-myc antibody 9E10 (Santa Cruz); 
anti-G4 antibody (Santa Cruz); anti-HDAC2 antibody (Santa Cruz); anti-HA antibody (Roche) 
were used for immunoblotting for the respective proteins.
To immunoprecipitate the endogenous acetylated pRb, cell pellets of SAOS2, U20S, 
T98G, A31, C33A and HEK293 were lysed in IPH buffer (50mM Tris pH 8.0, 150mM NaCl, 
5mM EDTA, protease inhibitor cocktail (Calibiochem), 5jliM TSA (Sigma)), supplemented with 
0.5% NP-40. Protein concentrations of the extracts were determined using Bradford assay 
(BioRad). Protein-A-agarose was first incubated with anti-Rb antibodies IF-8 and C15 for 1-2 
hours at 4°C. The beads were washed 3 times with IPH buffer (with 0.5% NP-40), and incubated 
with cell extracts overnight at 4°C. After overnight incubation, the beads were washed three
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times with IPH buffer. Proteins bound to the beads were eluted with 3X SDS loading buffer and 
analysed by Western blotting using the appropriate antibodies.
All other immunoprécipitations described were earned out in the same way as above, 
with slight modification of the NP-40 concentration. To immunoprecipitate pRb with MDM2, 
the NP-40 in the lysis buffer was diluted to final of 0.1%. Subsequent washes were carried out in 
IPH buffer with 0.1% NP-40.
In vitro-pulldown Assays
For the pRb/MDM2 experiments, 2p,g of GST-pRb was actylated by Flag-p300 (FL) in a 
standard 30p,l reaction as described above, but using Ipl of lOmM non-radiolabelled acetyl-CoA 
instead. For unacetylated pRb samples, acétylation reactions were carried out without acetyl- 
CoA. After the acétylation reaction, the reaction mixture was incubated with Flag beads (Sigma) 
in 400|li1 of IPH buffer (0.5% NP-40) to remove Flag-p300. The supernatant was collected and 
immunoprecipitated with either anti-Ac ~K antibody or anti-Rb antibody to purify the acetylated 
and unacetylated pRb respectively. In vitro transcribed and translated MDM2 (Promega IVT 
manual) was incubated either with acetylated or unacetylated pRb to assess binding efficiency. 
After incubation, the beads were washed three times with IPH buffer (0.25% NP-40), and 
samples analysed on SDS-PAGE followed by Western blot analysis. Anti-MDM2 antibody 
H221 (Santa Cruz) was used to detect MDM2 binding to pRb.
To map the p300/NAP-2 binding domain(s), the indicated NAP-2 derivatives were in 
vitro transcribed and translated, and ^^S-labelled using TNT-coupled reticulocyte lysate system 
(Promega) and incubated with GST-beads loaded with the indicated fusion proteins in IPH 
buffer (0.5% NP-40). After incubation at 4°C for 2 hours, the beads were washed three times in 
1ml of IPH buffer. Proteins bound to the beads were eluted with 3X SDS loading buffer and 
analysed by SDS-PAGE, followed by autoradiography. Similar experimental procedures were
47
used for identifying NAP-NAP interaction domains. All mapping experiments were repeated at 
least twice to ensure the reproducibility of the results. All in vitro pulldown assays described in 
chapter 5 were canied out in the same way as described above.
Cell cycle analysis
For flow cytometry analysis, lOpg of an expression vector for the cell surface protein 
CD20 was CO-transfected into cells (grown in 10% FCS) together with lOpig of the indicated 
pCDNA3-9E10-pRb plasmids. Cells were washed and refed after 16 hour of transfection, and 
harvested 40-48 hour later by washing in PBS and thereafter treating with cell dissociation 
medium (Sigma) for 15 minutes. Cells were washed in DMEM by centrifuging at 700rpm and 
resuspended in a small volume of DMEM containing the anti-CD20 antibody leu 16 (Becton 
Dickinson) coupled to fluorescein isothiocyanate (FITC). Cells were incubated upon ice for 45 
minutes, further washed twice in PBS and then resuspended in 50% PBS in ethanol at 4°C 
overnight. Cells were collected by centrifugation and treated with RNase (125U/ml) for 30 
minutes, harvested by centrifugation and suspended in propidium iodide (20pg/ml) in PBS at 
4°C 30 minutes. Flow cytometry was performed on a Becton Dickinson fluorescence activated 
cell sorter. The intensity of propidium iodine staining was analysed in cell populations that were 
positive for FITC staining to determine the cell cycle profile of the transfected population using 
the Consort 30 software. The data presented shows a representative example from multiple 
assays.
Mass spectroscopy and peptide sequencing
Acétylation of the synthetic peptide was carried out in a standard procedure described in 
the section of in vitro acétylation, with un-radiolabelled acetyl-CoA (l|xl of lOmM stock). The 
peptide sequencing was carried out at Welmet, Edinburgh University. All mass spectroscopy
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analysis was performed in Micromass Ltd, Wythenshawe, UK (please see appendix for details). 
Experts in Micromass UK Ltd (Wythenshawe) carried out sample preparation prior to mass 
spectroscopy analysis. In short, the samples were first desalted by means of a C l8 Ziptip, and 
diluted to approximately 2pm/|al in 50%MeOH plus 0.1% HCOOH prior to ESI-MS analysis. 
Electrospray MS and MS/MS data were acquired on a micromass Q-Tof mass spectrometer 
(Wythenshawe, UK.), fitted with a Z-spray nanoflow electrospray ion soui'ce. For details of the 
procedure, please see appendix for report directly submitted from Micromass.
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Chapter 3: Acétylation Control of the retinoblastoma tumour 
suppressor protein
Introduction
pRb and p300 are targets of the viral oncoprotein E lA  (182, reviewed in 42, 118 and 
references therein). E lA  mediates a trimeric complex between pRb/ElA/p300, and this complex 
is important for ElA-mediated transformation (155, 173). While E lA  mutants deficient in 
binding to pRb or p300 fail to transform cells, the transformation ability can be restored when 
the mutants are co-infected into the cells (173). However, the restored transformation is at least 
ten times less efficient when compared to the wild type, indicating the significance of the 
complex.
After p300 was cloned (44), it was recognised as a versatile transcriptional co-activator 
(5, reviewed in 52, 75, 147). Subsequently, the p300/CBP family of proteins was found to 
possess HAT activity (12, 128), which transfers an acetyl- group to the e-side chain of the lysine 
residue. In general, acétylation correlates with transcriptional activation and deacetylation 
correlates with transcriptional repression (reviewed in 20, 60). In the eaily 90s, only 
chromosomal proteins such as histones and HMG proteins were known to be acetylated. Studies 
during the last decade suggest that acétylation might alter chromosomal structure, facilitate 
chromatin remodelling, and regulate transcription. Recently, a growing list of transcription 
factors such as p53 (56), HIV-1 Tat (78), GATA-1 (17), myo-D (141), EKLF (195), c-Myb 
(161) and E2F (110, 111), were reported to be acetylated by p300/CBP and/or pCAF. 
Acétylation of most of these transcription factors resulted in enhanced DNA binding activity. 
Acétylation of p53 was shown to be stress-inducible, and correlates with certain phosphorylation 
events in p53 (100, 139). Acétylation of E2F-1 enhances its stability (110). Interestingly, one
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example also exists whereby acétylation can inhibit transcriptional activation. Acetylated dCTF 
inhibits its binding to Aimadillo, thereby down-regulating transcription (172). An emerging 
theme suggests that acétylation might mimic phosphorylation in controlling protein activity (15).
pRb is an intensively studied tumour suppressor protein (reviewed in 43, 62). 
Phosphorylation control of pRb by G1 cyclin-dependent kinases plays an important role in 
regulating pRb function (reviewed in 115, 149). Most of the pRb’s growth suppressive 
properties are ascribed to its ability to sequester the E2F family of transcription factors 
(reviewed in 43, 62 and references therein). During GO/Gl hypophosphorylated pRb binds to 
E2F, inactivating E2F-dependent transcription and thereby preventing cell cycle progression. 
Cyclin D/cdk4/6 and cyclin E/cdk2 progressively phosphorylate pRb at late G1 to early S phase. 
In S phase, pRb phosphorylation is maintained by cyclin A/cdk2.
pRb binds to the rranjactivation domain of E2F, providing a simple model of how pRb 
inhibits E2F-dependent transcription. In addition, pRb possesses intrinsic transcription 
repression activity, which is independent of its association with E2F (177). The identification of 
HDACs (18, 103, 106) as pRb binding proteins suggests a second mechanism in which 
transcriptional repression is achieved by recruiting HDACs to promoters to deacetylate histones. 
Furthermore, hSWFSNF complexes, which are ATPase-dependent chromatin remodelling 
factors, exist in a ternary complex with pRb and HDACs, further substantiating pRb’s role in 
regulating transcription via chromatin remodelling related mechanisms (196). Both E lA  and E7 
block pRb binding to HDACs, providing an additional mechanism for their oncogenic activity. 
Interestingly, pRb also binds to a HAT, TAFn250, which is the largest subunit of TFIID (116, 
143, 144). Whilst pRb was shown to inhibit the intrinsic kinase activity of TAFn250 (150), it is 
unclear if pRb also regulates TAFu250 HAT activity.
Here, evidence is presented to indicate that pRb is acetylated both in vitro and in vivo. In 
vitro acétylation assays were carried out which identified that the pRb family member pl07, and
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the pRb target E2F-1, were also acetylated by p300. While E2F-1 was acetylated by both p300 
and pCAF, pRb was only acetylated by p300. Domain mapping experiments suggested that pRb 
is acetylated in the pocket and in the C-terminal region. Furthermore, Ad E lA  enhanced pRb 
acétylation via a physical interaction mediated by its N-terminal transformation-sensitive 
domain. The MDM2 oncoprotein was found to interact more efficiently with the acetylated form 
of pRb. Site-directed mutagenesis studies identified residue K873, 874 as two possible lysines 
directly acetylated by p300 in vitro. When these lysines were mutated to glutamine, which might 
mimic the acetylated status of the lysine, the mutants showed defects in phosphorylation by 
cyclin/CDK complexes in vivo. Overall, the study suggests that pRb acétylation is an additional 
mechanism in regulation of pRb function.
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Results
In order to investigate if components of the pRb/E2F pathway are subject to acétylation 
control, recombinant pRb, E2F-1, cyclin D, pl07 and various other substrates were screened in 
an in vitro acétylation assay. The enzymes used in the in vitro acétylation assay included 
recombinant Flag-p300 (FL), Flag-p300^^^^‘^ '*^ '* and Flag-pCAF purified from sf9 insect cells 
infected with the respective baculovirus, or His-p300^^^^‘^ ‘’^  ^ (which contains the minimal HAT 
domain of p300) purified from bacteria (Fig 3.1a and data not shown). From this initial 
screening, pRb, p i07, E2F-1, p53, histones and ElA  were shown to be acetylated (Fig 3.1b). 
Furthermore, both p300 and pCAF were found to be auto-acetylated (Fig 3.3b, 3.7b and data not 
shown).
pRb, p107 and E2F-1 are acetylated in vitro
Using in vitro acétylation assays, pRb and its family member pl07 were shown to be 
acetylated by p300, but not by pCAF (Fig 3.2c). Furthermore, pRb and p i07 can be acetylated 
with the minimal HAT domain of p300 (Fig 3.2c, left panel). Two pRb pocket mutants, A21 and 
A22, show much reduced levels of acétylation (Fig 3.2c), suggesting the integrity of the pocket is 
important for efficient acétylation. In the same experiments, pRb C-terminal region was found to 
be efficiently acetylated (Fig 3.2c). Interestingly, in these assays, E2F-1 was found to be 
acetylated by both pCAF and p300 (Fig 3.2c, middle and right panel). While E2F-1 was poorly 
acetylated by the minimal HAT domain of p300, Flag-p300^^^ '^ '^* ‘^* efficiently acetylated E2F-1. 
Previously, the C-terminal region of p300 was shown to interact with E2F-1 (165), indicating 
efficient acétylation of E2F-1 by p300 requires the E2F-1 binding domain in p300. In this study, 
efforts were concentrated on understanding the role of pRb acétylation.
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pRb is acetylated in vivo
Whilst pRb was found to be acetylated in vitro, it was important to substantiate these 
findings in vivo. Two commercially available antibodies against anti-Ac-K were characterised to 
specifically recognise in vitro acetylated proteins, including in vitro acetylated pRb, E2F-1 and 
p300 (Fig 3.3a and b and data not shown). These antibodies were subsequently used to 
investigate whether pRb is acetylated in vivo. Since the antibody against Ac-K (New England 
Biolab) had much reduced background in immunoblotting (compare Fig 3.3b to Fig 3.3a), and 
showed a clear specificity in the immunoprécipitation assay (Fig 3.3c, compare track 2 with 6), 
all work presented in this thesis used this particular antibody to detect and immunoprecipitate 
acetylated forms of pRb. To investigate if pRb is acetylated in vivo, SAOS2, U20S and C33A 
cells were over-expressed with pRb, and treated with TSA prior to harvesting. 
Immunoprécipitations were performed using anti-Rb antibodies and control antibodies, followed 
by immunoblotting with the anti-Ac-K antibody. The anti-Ac-K antibody recognised a specific 
polypeptide from the sample immunoprecipitated with the anti-Rb antibody with a molecular 
weight of 105 KDa, but not in the control sample (Kristie-Demonacos et. al, personal 
communication). Using the same experimental procedure, further evidence that pRb is acetylated 
under physiological conditions was demonstrated when endogenous pRb was found to be 
acetylated in 293 HEK cells (Fig 3.3d, middle panel, track 2). Althought similar amount of pRb 
was immunoprecipitated from 293 HEK, U20S and T98G cells (Fig 3.3d, top panel, track 2, 3 
and 4), no significant amount of endogenous pRb was found to be acetylated in U20S or T98G 
cells (Fig 3.3d, middle panel, track 3, 4). A31 (Fig 3.3d, track 5) is a murine cell line, and since 
the pRb antibodies did not immunoprecipitate murine pRb (Fig 3.3d, top panel, track 5), this cell 
line was used as a negative control in the experiment. Furthermore, SAOS2 cell, which is Rb''\
54
was also used as negative control for the immunoprécipitation and immunoblotting of pRb (Fig 
3.3d, top panel, track 6).
Domain Mapping of Acétylation sites in pRb
Since the pRb pocket mutant A21 and A22 have diminished levels of acétylation, 
investigation was undertaken to determine if the regions deleted in these mutants contain site(s) 
for acétylation. From the three dimensional structure of the pRb A/B pocket in complex with the 
E7 peptide (94), a group of conserved and functionally important lysine residues (K713, 720, 
722, 729) were implicated in exons 21 and 22 (also see chapter 5, Fig 5. Ic and d). A peptide (Fig 
3.4a) covering this region was synthesized and tested in the in vitro acétylation assay. The 
peptide was acetylated in vitro by p300, and mass spectroscopy analysis suggested that the 
peptide was singly acetylated (Fig 3.4c). Using both mass spectroscopy analysis and peptide 
sequencing, it was found that the first lysine in the peptide (K713 in pRb) was predominantly 
acetylated (Fig 3.4b, d and e). From peptide sequencing, the majority of the K713 was not 
modified (Fig 3.4b), as indicated by K in the spectrum. Approximately 10% of the K713 was 
acetylated, as indicated by Ac-K in the spectrum. This peak co-migrates at the same position as 
the acetylated-lysine amino acid standard. Also in the spectrum indicates the 5* amino acid in 
the peptide. Valine (V), of the peptide. This is a secondary peak due to the heterogenity of the 
peptide population.
In order to substantiate the result that K713 is the site of modification, site directed 
mutagenesis was earned out to mutate K713 to A or R (also see chapter 5, Fig 5.1). GST-pRb 
713KA and 713KR mutants, which had the K713 mutated to A and R respectively, exhibited a 
slight reduction in the level of acétylation when compared to the wild type protein (Fig 3.5b and 
c). Therefore, there are other lysine residue(s) apart from K713 that can be acetylated by p300 in 
vitro.
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In order to define the general domain(s) of acétylation in pRb, various GST-pRB fusion 
proteins were purified and tested in the in vitro acétylation assays. GST-pRb (379-656), which 
contains the A pocket and the linker region, showed a low, but detectable level of acétylation 
(Fig 3.6b). GST-pRb (641-775), which contains the B pocket, had an undetectable level of 
acétylation (Fig 3.6b). However, one particular problem with GST-pRb (641-775) was that it 
generated much less recombinant protein from the purification. Two more GST-pRb fusion 
constructs containing the B pocket were made to try to overcome this problem, namely GST- 
pRb (702-766) and GST-pRb (702-792). However, neither of these consti'ucts yielded significant 
amounts of recombinant protein (data not shown). Therefore, it is not clear whether or not the B 
pocket can be acetylated in vitro. It is very likely that under these conditions, truncation within 
the pRb small pocket will not yield properly folded proteins, which might therefore complicate 
the interpretation of the data, and no further detailed domain mapping was carried out within the 
small pocket. The C terminal region of pRb however was strongly acetylated by p300 in vitro 
(Fig 3.2 and 3.6). By studying the acétylation of an extensive panel of mutant derivatives taken 
from the C-terminus, the major regions of acétylation were mapped to residues between 794-829 
and 830 to 884 (Fig 3.6d and f). GST-pRb (881-928), which contains seven lysine residues, 
failed to be acetylated. In conclusion, multiple domains on pRb can be acetylated. In the C- 
terminus, the major sites of acétylation occur on lysine residues within region of 794-881, which 
contains 8 lysines altogether.
pRb acétylation by p300 is enhanced by E1A
Both pRb and p300 are targets of viral oncoprotein ElA, and a ternary complex can be 
formed of pRb, p300, and E lA  (45, 173). 293 HEK is a cell line which contains endogenous 
ElA. Using anti-Rb antibodies for immunoprécipitation, p300 was indeed detected in 
immunoprecipitates from 293 HEK cells (Fig 3.3d, bottom panel, track 2). Anti-Rb antibodies
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did not immunoprecipitate a detectable level of p300 from cell lines (U20S, T98G, C33A) 
lacking E lA  expression (Fig 3.3d and data not shown). Furthermore, an in vitro binding assay 
using recombinant ElA, pRb and p300 also indicated that E lA  could mediate the formation of 
the trimeric complex (data not shown).
There are contradicting reports regarding E lA ’s ability to regulate p300 HAT activity 
(2, 25, and 58). Given the ability of E lA  to mediate the formation of pRb/ElA/p300 ternary 
complex, experiments were carried out to determine if E lA  affects p300’s ability to acetylate 
pRb. By titrating His-EIA (13S), E lA  enhanced pRb acétylation (Fig 3.7b). This effect is 
specific to pRb as in the same experiment, His-EIA inhibited E2F-1 acétylation, and caused a 
moderate change in the level of histone acétylation (a slight stimulation of 1.8 fold with 0.3jag of 
ElA, Fig 3.7b). Furthermore, E lA  did not significantly alter p300 autoacetylation. To further 
verify that E lA  enhances pRb acétylation by p300, a GST-EIA (12S) fusion protein was 
purified, and similar experiments were performed. Consistent with the result observed with His- 
EIA, GST-EIA also enhanced pRb acétylation at range where there was less E lA  protein 
compared to pRb protein (molar ratio of E lA  to pRb is approximately 1:1 in Fig 3.7c, track 4). 
When the molar ratio of E lA  to pRb was about 5:1 (Fig 3.7c, top panel, track 5), the 
enhancement of pRb acétylation was lost. However, it is clear that under those conditions, E lA  
did not repress pRb acétylation by p300. GST-EIA specifically enhanced pRb acétylation as p53 
acétylation was reduced by GST-EIA at all concentrations in the same experiment (Fig 7c, 
bottom panel).
Next, experiments were performed to identify the domains of E lA  which are required to 
enhance pRb acétylation. A panel of GST-EIA mutants were created to answer the question. The 
N-terminus deletion mutant A36 is defective in binding to p300 (173). The pm928 mutant has 
been previously reported to be defective in binding to pRb (173). The ACRl and ACR2 mutants
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contain deletions in the conserved region 1 and 2 of E lA  respectively, and invariably they were 
reported to be defective in binding to pRb (9). In vitro acétylation experiments with various ElA  
mutants suggested that all E lA  mutants were defective in enhancing pRb acétylation when 
compared to the wild type (Fig 3.8b, d, and e). The ElA  A36 mutant was completely inactive in 
enhancing pRb acétylation by p300. Therefore, E lA  requires both the p300 and pRb binding 
domains to enhance pRb acétylation. These observations are consistent with the idea that ElA, 
by mediating a ternary complex among the three proteins, actively directs the p300 HAT activity 
to acetylate pRb.
Acétylation of pRb enhances pRb/MDM2 interaction
The C-terminal region of pRb is known to contribute to pRb tumour suppressor function, 
and was reported to bind to the oncoprotein MDM2 (64, 135, 183). Using a panel of GST-pRb 
C-terminus derivatives (Fig 3.9a), the minimal domain in pRb for binding to MDM2 was 
mapped to residues 792-928, which agrees with previous reports (183). Experiments were 
performed to investigate if pRb acétylation affects its interaction with MDM2. In the in vitro 
pulldown assay, MDM2 preferentially interacted with the acetylated form of pRb (Fig 3.9b). 
Furthermore, immunoprécipitation experiments using anti-Rb antibodies demonstrated the 
presence of an easily detectable complex between pRb and MDM2 in 293 HEK cells, but not in 
U20S or T98G cells (Fig 3.9c). As shown in previous section, 293 HEK cells contain significant 
amounts of acetylated pRb (Fig 3.3d). When T98G cells were treated with Trichostatin A (TSA), 
which is a deacetylase inhibitor (103, 127) and therefore presumably enhances pRb acétylation 
level, it was also found to have an increased amount of MDM2 in the immunocomplex with pRb 
(Fig 3.9d). TSA treatment did not change MDM2 and p53 protein level (Fig 3.9d and data not 
shown), though it was noted that pRb was shifted to a hypophosphorylated status (Fig 3.9d and 
data not shown). These findings are consistent with previous reports (127). The in vivo
58
immunoprécipitation results are consistent with the findings of the in vitro binding assay, 
suggesting that MDM2 preferentially binds to the acetylated pRb.
Lys873/874 are important in regulating pRb phsophorylation by CDKs
One particular domain in the pRb C-terminal region (residues 830-884) was shown to be 
efficiently acetylated by p300 in vitro and was reported to contain sequences that are important 
in regulating pRb phosphorylation by cyclin/CDK complexes (1). Careful analysis of the 
sequence identified a lysine-rich stretch (KXXKK), which also showed some homology in other 
proteins which were found to be acetylated (Fig 3.10b). To investigated if these lysines might be 
regulated by acétylation, site-directed mutagenesis was carried out to mutate K873, 874 to 
arginine (RR), which will maintain the overall basic charge but cannot be acetylated, and 
therefore to mimic the unacetylated state; or to glutamine (QQ), which is expected to mimic the 
acetylated state of lysine (194). The K to Q mutation was widely used in studying how 
acétylation of the histone tails affects transcriptional regulation (194). When the GST-pRb (830- 
884)RR mutant was tested in the in vitro acétylation assay, no detectable acétylation was 
observed (Fig 3.10c). This suggests that K873/874 are residues modified by p300 in vitro. 
Overall, two critical lysine residues were identified; the mutation of which abolishes pRb 
acétylation in the region from amino acid 830-884.
Next, experiments were carried out to understand the functional significance of 
K873/874, in particular the role in regulating pRb phosphorylation by CDKs. First, the RR and 
QQ mutations were introduced into the full-length pRb. When the 873/874RR mutant was 
transfected into SA0S2 or U20S cells, it behaved similarly as the wild type pRb to be 
phosphorylated to equivalent level (Fig 3.10d and e). However, the 873/874QQ mutant, which 
might mimic the acetylated state of the protein, showed a defect of phophorylation in both 
SAOS2 and U20S cells (Fig 3.10d and e). In SA0S2 cells, the 873/874QQ mutants showed
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incomplete phosphorylation upon expression of exogenous cyclin E/CDK2 when compared to 
the wild-type pRb or the 873/874RR mutant. U20S cells were known to contain hyperactive 
endogenous CDK activity. Overexpression of pRb in U20S cells showed accumulation of both 
the hypo- and hyperphosphorylated pRb (Fig 3.10e, track 2). While the 873/874RR mutant 
behaved similarly to the wild type pRb (Fig 3.10e, track 3), the 873/874QQ mutant showed 
defects in phosphorylation by endogenous CDKs, and accumulated in the hypophosphorylated 
form (Fig 3.10e, track 4). In conclusion, K873/874 aie important in regulating pRb 
phosphorylation by cyclin/CDK complexes.
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Discussion
The acétylation of pRb described here suggests an additional level of regulation of its 
activity. Although viral oncoprotein E l A recruits p300 and pRb into a ternary complex (42, 
118), the functional significance of this complex is not well understood. E l A requires binding to 
both pRb and p300 for its transformation function (118, 173). With the demonstration that E l A 
enhances pRb acétylation by p300 comes the possibility that E lA  acts to re-direct p300 HAT 
activity to modify pRb function. Furthermore, both E2F-1 (110, 111) and p53 (56, 100, 139) aie 
known to be acetylated. It is very interesting to note that the two most studied tumour suppressor 
pathways, namely, the E2F/pRb and the p53 pathways, all subject to acétylation control. It was 
demonstrated that the acétylation of E2F-1 and p53 enhance their DNA binding activity. 
Detailed investigation of p53 acétylation demonstrates that p53 acétylation at the C-terminal 
region is stress-inducible, and probably directed by phosphorylation of S-33 and -37 in the N- 
terminal region (100, 139). Taken together, the data suggest that acétylation plays a role in 
regulating the p53 and E2F/pRb pathways. E lA  also directly tai’gets the two HATs, p300 and 
pCAF, used in the study (188), arguing that the disruption of the normal acétylation control of 
the p53 and E2F/pRb pathways by p300/pCAF could be an important feature of E lA  oncogenic 
activity. Since E lA  was found to enhance pRb acétylation, but reduce E2F-1 and p53 
acétylation, the acétylation of pRb may inactivate its growth suppressive functions, whilst the 
acétylation of E2F-1 and p53 may enhance their tumour suppression functions. Further studies 
will be required to address these issues.
Post-translational phosphorylation control of pRb by G1 CDKs plays a major role in 
regulating pRb function (reviewed in 115). There aie sixteen potential consensus 
phosphorylation sites in pRb. Phosphorylation at S-807 and -811 was demonstrated to release
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the interaction of c-Abl from pRb (84). In contrast, the pRb/E2F interaction appears to be 
regulated by a number of phosphorylation sites in the C-terminal region, and possibly involving 
two serines in the spacer domain (85, 168). Phosphorylation at the pRb C-terminus by CDK4/6 
initiates successive intramolecular interactions between the C-terminal region and the pocket 
domain which progressively inactivate pRb function (59). In parallel to pRb phosphorylation, 
this study shows that multiple domains on pRb can be acetylated. They occur both in the pocket 
and in the C-terminal region. It has so far not been tested whether acétylation occurs in the N- 
terminal region of the protein. In this respect, it will be crucial to further characterise the precise 
acétylation sites on pRb in vitro and in vivo. It is possible that the acétylation of pRb will have 
multiple effects on its functions, depending upon which residue(s) or combinations of residues 
are acetylated. While E lA  enhances pRb acétylation, it will be interesting to determine whether 
E lA  also alters the pattern of acétylation on pRb by preferentially enhancing acétylation at 
certain specific residues. Unlike the case of phosphorylation, there are no good consensus 
sequences for acétylation. Therefore, in the cunent study, it was difficult to identify the specific 
lysine residues modified by p300. It will be important to characterize all lysine residues which 
are modified by acétylation in vitro and in vivo. With the ever increasing power and resolution of 
the biophysical techniques using 2D gel analysis coupled to mass spectroscopy, this will be one 
way to identify the lysine residues acetylated in pRb. As demonstrated in this study, mass 
spectroscopy analysis successfully identified one lysine acetylated in a synthetic peptide. With 
the knowledge of the precise acétylation sites in pRb, mutagenesis studies could then be used to 
generate interesting information on how acétylation affects pRb function.
Since the C-terminal region of pRb was found to be the major domain to be acetylated, 
this leads to the question of how the acétylation in the pRb C-terminus affects its function. 
MDM2 is an oncoprotein known to bind to the C-terminal region (183). In vitro biochemical 
binding data suggest that acetylated pRb preferentially binds to MDM2. MDM2 was also found
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to efficiently complex with pRb in 293 HEK cells which contain a relatively high level of 
acetylated pRb when compared to the other cell lines used in the study. Treatment of T98G cells 
with TSA, which is a deacetylase inhibitor and therefore is likely to enhance pRb acétylation, 
also enhanced MDM2 binding to pRb. Whilst these in vivo data are not exclusive proof that pRb 
acétylation enhances its interaction with MDM2, the findings are consistent with the in vitro data 
and suggest that acétylation regulates pRb-MDM2 interaction.
MDM2 was reported to inhibit pRb growth regulatory functions (183), possibly by 
relieving pRb from E2F. Furthermore, MDM2 can confer TGF-p resistance, possibly by 
interacting with the E2F/pRb pathway (156). Both reports provide evidence that MDM2 binding 
to pRb abrogates pRb growth suppression functions. These studies also provide a logic for ElA  
to enhance pRb acétylation, and therefore contribute to E lA ’s oncogenic activity. It is also to be 
noted that E lA  can induce p53 and promotes apoptosis in primary cells, which is reflected in 
E lA ’s ability to enhance radio- and chemosensitivity (37). Interestingly, pRb binding to MDM2 
was found to overcome both the anti-apoptotic function of MDM2 and the MDM2-dependent 
degradation of p53 (64). Therefore, the observation of enhanced MDM2 binding to acetylated 
pRb could be one explanation towards E lA ’s apoptotic function.
Although abundant evidence suggests that pRb phosphorylation is essential for cellular 
growth and proliferation, counter evidence also exists to suggest that there are other mechanisms 
which might bypass the need for pRb phosphorylation in driving cellular progression (reviewed 
in 115, and references therein). For example, it has been shown that the combined expression of 
c-Myc and oncogenic Ras allows entry of growth-factor-deprived REF 52 cells into S phase and 
does so without detectable pRb phosphorylation. Furthermore, overexpression of cyclin E also 
triggers S phase entry in cells expressing pRb lacking 10 out of the 16 CDK phosphorylation 
sites. It will be interesting to conelates the acétylation status of pRb in different phases of the 
cell cycle and determine if pRb acétylation is essential for cellular growth.
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Mutational analysis of K873 and 874 identified these residues as potential targets of 
acétylation by p300 in vitro, though it has yet to be verified that they are targets of acétylation in 
vivo. An alternative explanation is that these lysines are part of a subtle consensus sequence 
important for acétylation. Therefore, mutations in these lysine residues may render other lysines 
un-acetylatable. Interestingly, these two residues are within the KPLKKL motif which was 
found to be important for pRb phosphorylation by cyclin-CDK2 complexes (1). Indeed, when 
the K873/874 was mutated to QQ, which might mimic the acetylated form of the protein, the 
mutant protein was defective in phosphorylation by cyclin/CDK complexes in both SA0S2 and 
U20S cells. This suggests that there might be cross regulation between phosphorylation and 
acétylation. These findings are consistent with the model that acétylation of pRb has multiple 
functions. Since E2F is the most studied target of pRb, an investigation was carried out to 
determine if pRb acétylation affects its binding to E2F (data not shown). In vitro binding assays 
suggested that E2F-1 binds to the acetylated pRb, though these assays were not sensitive enough 
to determine if the affinity of the binding was affected upon acétylation. Given that the pocket 
domain was found to be acetylated in vitro, it will be important in future studies to investigate 
how acétylation changes the pocket function.
In the current study, pRb was found to be acetylated only by p300, but not by pCAF. 
This suggests a level of specificity in HATs. It is interesting to note that pRb also interacts with 
another HAT, TAFn250, which is the lai'gest subunits of the TFIID complex (143, 144). 
Previous studies suggested that pRb can inhibit the intrinsic kinase activity of TAFu250, though 
pRb was not acetylated by TAFn250 (150). TAFu250 HAT activity is required for cell cycle 
progression (41). It will be worthwhile to investigate if pRb affects TAFn250 HAT activity. 
Immunoprécipitation of pRb from U20S, T98G and C33A cells, followed by immunoblotting 
with anti-Ac-K antibody indicated that there was an undetectable level of acetylated pRb under 
normal conditions. Similar to the case of p53 acétylation, only a low level of pRb protein seems
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to be acetylated in the cells. In 293 HEK cells, which are transformed with ElA, a significant 
amount of acetylated pRb was observed. It will be important to understand how pRb acétylation 
is regulated in the cell. Since p53 acétylation was stimulated after treatment with DNA 
damaging agents such as UV and ionizing radiation (100, 139), experiments were caiTied out to 
determine if pRb acétylation might be similarly regulated. However, no detectable pRb 
acétylation was observed when U20S cells were treated with actinomycin D (data not shown). 
Since pRb is hyperphosphorylated in U20S cells, and therefore functionally inactive, this cell 
line might not be most suitable for that particular purpose. Similar experiments need to be 
repeated in other cell lines with an intact pRb/E2F pathway.
While E lA  can bridge together a trimeric complex of pRb and p300, a cellular protein 
with similar activity has not been reported. MDM2 can bind to both p300 and pRb. Furthermore, 
p300 and pRb binds to non-overlapping domains on MDM2 (53, 64). In vitro binding 
experiments were performed using purified pRb and p300 proteins, together with in vitro 
translated MDM2 to determine if pRb/p300/MDM2 can be in a trimeric complex (data not 
shown). No trimeric complex was detected. It is very intriguing to speculate how pRb is 
recruited to p300 under normal conditions. Although p300 specifically acetylates pRb in vitro, 
evidence is still lacking that it is the HAT which acetylates pRb in vivo. It will be essential to 
identify the HAT(s) which acetylate pRb in the cell.
In conclusion, this report identifies an additional post-translational mechanism involved 
in regulating pRb function, namely acétylation. Given that the acétylation pathway is targeted by 
viral oncoprotein ElA, this indicates the potential significance of acétylation control on pRb. 
Future tasks remain to identify the precise acétylation sites on pRb, the HATs acetylating pRb 
under physiological conditions, and the functional consequences of pRb acétylation.
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Figure 3.1 Purification of Flag-p300/pCAF and table of summary of the in vitro acétylation results
a) Purification of Flag-p300 and Flag-pCAF
Flag-p300, pCAF and were purified from sf9 cell extracts infected with the
respective baculovirus (sf9 extracts in lane 1, 2 and 5). The purified proteins (lane 3, 4 and 6) are
indicated by The gels were stained with coomassie blue.
b) Summary of various substrates tested for acétylation in vitro using the indicated HAT. Substrates
which were acetylated (+) and not acetylated (-) are indicated. NA (not applicable) means the
tests were not performed.
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Figure 3.2
The pRb, p l07  and E2F-1 are acetylated in vitro.
a) Schematic representation of various GST-Rb fusion proteins, GST-E2F-1 and GST-pl07 used in 
the acétylation assays.
b) The indicated GST-Rb, E2F-1 and p l07  fusion proteins were expressed, purified and analysed on 
an SDS gel. The gel was stained with coomassie blue.
c) Autoradiograph of GST-fusion proteins acetylated by p300 and pCAF. The indicated GST-fusion 
proteins (2|ig) were incubated with the indicated HATs (about 0.3jLig) and ‘^^ C-acetyl-CoA. The 
left panel shows the acétylation assay using His-p300^^^^"'^^, which contains the minimal HAT 
domain of p300. The middle panel shows the acétylation assay using Flag-p300 (FL) and the 
right panel shows the acétylation assay using Flag-pCAF.
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Figure 3.3
The retinoblastoma protein is acetylated in vivo.
a) Anti-Ac-H4 antibody (Serotec) recognises in vitro acetylated GST-Rb. 2|Ug of the GST-Rb was 
incubated with 0.3pg of flag-p300"^^'^'^^'*, in a typical 30|il acétylation reaction either with or 
without l |i l  of lOmM acetyl-CoA. A titration of the reactions 1:3:6 was loaded into lane 1-3 with 
4-6. The upper panel shows a western blot using anti-Rb antibody C15, which indicates the input 
amount of GST-Rb. The lower panel shows a western blot using anti-Ac-H4 antibody which 
specifically recognises acetylated GST-Rb (compare lanes 1-3 with 4-6). The antibody also 
recognises acetylated p300.
b) Anti-Ac-K antibody (New England Biolab) specifically recognises in vitro acetylated GST-Rb.
The reactions were titrated 1:9 into lane 1, 2 and 3, 4. The upper panel shows a western blot using
anti-Rb antibody C15, which indicates the input amount of GST-Rb. The lower panel shows a
western blot using anti-Ac-K antibody which recognises acetylated GST-Rb (compare lane 2 
with 4). The antibody also recognises acetylated p300.
c) Anti-Ac-K antibody immunoprecipitates in vitro acetylated GST-Rb. Acetylated GST-Rb (lane
2) and unacetylated GST-Rb (lanes 3-6) samples were prepared by performing an in vitro 
acétylation assay in the presence (lane 2) or in the absence of acetyl-CoA (lanes 3-6). GST-Rb 
was immunoprecipitated using anti-Ac-K antibody (lanes 2 and 6) or anti-Rb antibody C l5 (lane
3), anti-Rb antibody IF-8 (lane 4) or direct pull-down using GST-beads (lane 5). Lane 7 and 8 
were controls for C l5 and IF-8 immunoprécipitation using purified GST protein. The 
immunoprecipitated samples were analysed by SDS-PAGE, followed by western blot using anti- 
Rb antibody C15. Lane 1 shows the input of purified GST-Rb. Anti-Ac-K antibody can 
specifically immunoprecipitate in vitro acetylated GST-pRb (compare lane 2 to 6). C15 and IF-8 
also immunoprecipitate GST-Rb (compare lanes 3, 4 with 7, 8).
d) Endogenous pRb is acetylated.
Extract from 293 HEK, U 20S, T98G, A31 and SAOS2 cells (lanes 2-6) were 
immmunoprecipitated with anti-pRb antibodies (CIS and IF-8), and thereafter immunoblotted
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with anti-pRb antibody (G3-245, top panel), anti-Ac-K antibody (middle), or anti-p300 antibody 
(N15, bottome panel). Lane 1 is the control for immunoprécipitation from 293 cells using an 
irrelevant control antibody. Note that although a similar level of pRb is immunoprecipitated from 
293, U 20S and T98G cells (lanes 2 to 4), only 293 HEK cells (which express E lA ) contain high 
levels of p300 and acetylated pRb in the immunocomplex. A31 is a mouse cell line, which 
contains an abundant level of pRb (lane 5). This experiment indicates that the anti-pRb antibodies 
used do not efficiently immunoprecipitate murine pRb. SA 0S2 cells is a Rb' '^ cell line, which is 
used as a control for the immunoprécipitation and immunoblotting (lane 6).
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Figure 3.4
Analysis of an in vitro acetylated peptide derived from pRb B pocket.
a) The sequence of the synthetic peptide from the pRb B pocket. The peptide covers exon 21, from
amino acid 710 to 732. Conversed lysine residues among pRb from different species are 
indicated.
b) 5p.g of the synthetic peptide was acetylated in vitro using 0.5p,g of Flag-p300” ^^ '^ '^ *‘^ . The 
acetylated peptide was sequenced by Edman degradation (Welmet) to identify the acetylated 
lysine. The top panel indicates the position of the acetylated lysine amino acid standard in the 
spectrum. The bottom spectrum shows the 4‘^ ' amino acid, which is K713 in pRb sequence.
c) The acetylated peptide was subjected to mass-spectroscopy analysis. The peptide has a relative
molecular mass of 2521.50. The expanded view of the spectrum shows a quadruply charged ion 
of low intensity at m/z 641.86 corresponding to the acetylated form of the peptide. The
unacetylated peptide gives a signal of m/z 631.38 (see appendix).
d) Analysis of the MS/MS spectrum of the ion at m/z 631.40 with MaxEnt III software to produce a 
singly charged and de-isotoped MS/MS spectrum. Using the PepSeq software, the C-terminus of 
the peptide was determined, and indicated no modification. The modification was indicated to be 
present on one of the first four" amino acids in the sequence (see appendix).
e) An expanded view of the region in m/z 50 to 500 indicated the expected mass spectral fragments 
of the first four amino acids of the pepide. The table indicates the expected spectral signal of the 
peptide sequence. In the spectrum, the presence of a peak corresponding to the acetylated lysine 
at 444.24, and the absence of a peak corresponding to the b4 fragment ion of the unmodified 
lysine at m/x402.22, strongly suggests the 4^  ^lysine (or K713 in pRb) is acetylated in the peptide 
(see appendix).
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Figure 3.5
Characterisation of the pRb 713KA and 713KR mutants.
a) Coomassie stain of the GST-Rb (lane 1 and 5), and GST-Rb mutants (713KA and 713KR lane 2, 
3 and 6, 7 respectively) used in the in vitro acétylation assay by Flag-pSOO^'^^’^ '^ '^^  (lane 1 to 3) 
and His-pSOO'^^^""^^ (lane 5-7). Lane 4 is a control using Flag-300'*^^'^'^‘'^ , but without any GST- 
Rb fusion proteins. Approximately, 2jLtg of the GST-fusion proteins and 0.3ftg of the p300 fusion 
proteins were used in the experiment. Acetylated protein is labeled with '^’C-acetyl-coA.
b) Autoradiograph of the in vitro acétylation of GST-Rb and GST-Rb mutants. Note: Rb mutants, 
713KA and 713KR have reduced level o f acétylation compared to the wild type (compare lanes 
2, 3 with lane 1 and compare lanes 6, 7 with lane 5).
c) Quantitation of the level o f acétylation of GST-Rb and pRb mutants in panel B. The intensity was 
normalised as intensity of the acetylated signal/intensity of input pRb protein. Wild type pRb was 
assigned with 100% of intensity. Both mutants have 65-80% of the wild type GST-Rb acétylation 
level.
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Figure 3.6
The C-terminal region of pRb is the major site of acétylation.
The indicated derivatives of pRb (a, c and e) were expressed and purified as GST-fusion proteins 
and analysed on a SDS gel by coomassie staining (bi and di). Each GST-pRb derivatives (about 2pg in b, 
and 5|Lig in d, f) was assesed for in vitro acétylation by Flag-p300^*^^’^ ‘*^ ‘^ (0.3pg) in the presence of *“*0- 
acetyl-CoA. Acetylated pRb and autoacetylated p300 are indicated (bii, cii and f), and GST alone input is 
shown (bii, cii, and f, all in track 1). The results indicated two discrete domains in the pRb C-terminal 
region, from amino acid 794-829, and 830-884 contains possible acetylated lysines. The extreme C- 
terminal region from 881-928, although contain seven lysines, was not acetylated by p300 in vitro. The A 
pocket fusion (379-656) (indicated by *) showed a very low, but detectable level o f acétylation by p300.
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Figure 3.7
E lA  enhances pRb acétylation, and inhibits E2F-1 and p53 acétylation by p300 in vitro.
a) Coomassie stain of GST-pRb (2pg), GST-E2F1 (2pg), chicken histones (Iflg) used in the
acétylation assay by Flag-p300“ ^^ '^ '*^ '* (0.3|ug). His-E1A13S was titrated into the reaction from 0, 
0.3, and Ipg into lanes 1-3, 4-6 and 1-9 respectively. The acetylated proteins were labeled with 
‘'^C-acetyl-CoA.
b) Autodiograph of acetylated GST-Rb, GST-E2F1 and histones. E lA  enhances GST-Rb
acétylation (compare lanes 2, 3 to 1), represses E2F-1 acétylation (compare lanes 5, 6 to lane 4) 
and does not significantly alter histone acétylation (compare lanes 7, 8 and 9). In this experiment, 
p300 autoacetylation is not significantly altered by the presence of E lA . H is-EIA  was also 
acetylated by p300 in vitro.
c) Autoradiograph of GST-Rb and GST-p53 acétylation by in vitro. Essentially the
same experimental procedure was used as above. About l|Ug of GST-Rb and 0.5p,g of GST-p53 
was acetylated by Flag-p300^^^^‘^ '^ '^^  in vitro. GST-E1A12S was titrated into the acétylation 
reaction from 0, 0.04, 0.2, 1, and 5jug (lanes 1-5). Lane 6 shows a control reaction using Ipg of 
GST alone. The top panel shows that GST-EIA enhances GST-Rb acétylation (compare lanes 3, 
4 to lane 1). At a high level of GST-EIA (lane 5), the enhancement of GST-Rb acétylation by 
E lA  was lost. The lower panel indicates GST-EIA represses GST-p53 acétylation (compare 
lanes 2-5 with lane 1). GST has no effect on pRb or p53 acétylation (compare lane 6 to lane 1).
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Figure 3.8
E lA  requires binding to both pRb and p300 to enhance pRb acétylation by p300 in vitro.
a) Schematic representation of E l A constructs used in the assay.
b) Phosphoimage of GST-Rb acetylated by Flag-p300^‘^^ ‘^ ' '^'‘. 2|ug of GST-Rb was incubated in the
presence of Ipg  GST, GST-EIA, GST-E1AA36 or GST-E1A928, and acetylated by 0.3fxg of 
Flag-p300*^^^'^'‘ '^*. Acetylated proteins are labeled with ''^C-acetyl-coA. Lane indicated with (-) 
shows control with BClOO buffer alone.
c) Quantitaion of p300 auto-acetylation from the phosphoimage in b).
d) Quantitaion of pRb acétylation from the phosphoimage in b).
e) Quantitaion of pRb acétylation from another experiment using the same experimental procedure
and conditions as described in b). Two other E lA  mutants, ACRl and ACR2, which are defective 
in pRb binding, were included in the assay. Control using BClOO alone is indicated as -, All three 
E lA  mutants have reduced ability to enhance pRb acétylation by p300 in vitro.
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Figure 3.9
Acétylation of pRb enhances pRb binding to oncoprotein MDM2.
a) Summary of results of domain mapping of MDM2 binding to the C-terminal region of pRb. GST- 
Rb 792-928 was found to be the minimal domain required for binding to MDM2.
b) GST-Rb was acetylated by Flag-p300 (FL) in vitro using non-radiolabeled acetyl-CoA.
Unacetylated pRb control was prepared in an identical acétylation reaction but omitting acetyl- 
CoA. After completion of the acétylation reaction, Flag-p300 was removed using Flag-beads 
(Sigma). The supernatant was immunoprecipitated using either anti-Ac-K antibody or anti-pRb 
antibody (C l5) to purify the acetylated and unacetylated GST-pRb respectively. The lower panel 
shows input pRb used in the pulldown assay against in vitro transcribed and translated MDM2. 
Note that acetylated pRb binds more efficiently to MDM2 in vitro (compare lane 3 to 2, top 
panel).
c) Extracts from the indicated cell lines (SA0S2, U 20S, T98G and 293 HEK) were
immunoprecipitated with anti-Rb antibodies (IF-8) and, thereafter analysed by SDS-PAGE and 
immunoblotted with either anti-Rb antibodies (G3-245, top panel), or anti-MDM2 (H-221, 
middle panel). A high level of co-immunoprecipitated MDM2 was seen in the pRB 
immunocomplex from 293 cell extracts. SAGS2 cells are Rb''\ and were used as negative control 
for the immunoprécipitation and immunoblotting. The bottom panel show input protein level of 
MDM2 from various cell lines.
d) Extracts prepared from T98G cells either treated with or without TSA (5pM) for 10-20h, and
untreated SA 0S2 cells were immunoprecipitated with anti-pRb (C15 and IF-8) antibodies and 
after electrophoresis immunoblotted with either anti-pRb G3-245 (top) or anti-MDM2 (middle) 
monoclonal antibody. An increased amount of MDM2 was found in the pRb immunocomplex 
from TSA-treated T98G cells. In lane 1, SA 0S2 cell extract was used for control of the 
immunoprécipitation and immunoblotting. The bottom panel indicates the input o f MDM2 
protein level.
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Figure 3.10
Acétylation at the pRb C-terminus (K873/874) influences pRb phosphorylation by cdk complexes.
a) The sequence motif previously indicated to be important in regulating pRb phosphorylation. The 
lysine resiudes 873, 874 were mutated to arginine (R) or glutamine (Q) as indicated.
b) Sequence comparison of a lysine sequence found to be acetylated in various proteins. A KXXK 
m otif may confer a general consensus sequence for acétylation. The acetylated lysines are 
indicated in bold.
c) In vitro acétylation of the indicated derivatives (2|ig) of GST-pRb (830-884), or GST-pRb (830- 
884)RR. The top panel shows the coomassie staining of the purified proteins (WT for GST-pRb 
(830-884); RR for GST-pRb (830-884)RR) and the lower panel shows the autoradiograph of the 
acetylated proteins.
d) In vivo phosphorylation of the indicated derivatives of full-length pRb, namely the wide type 
pRb, 873/874RR and 873/874QQ. SA 0S2 cells were transfected with pRb (lOpg) in the presence 
or absence of cyclinE/cdk2 (4pg each). Lane 1 is a control of untransfected SAOS2 cell. After 36 
hour of transfection, 75pg of the whole cell extract was immunoblotted with anti-pRb (G3-245). 
The position of the hyper- (+) and hypo- (-) phosphorylated (?) pRb is indicated.
e) In vivo phosphorylation of pRb and mutant in U 20S cells. Same procedure as described in d), but 
without expressing exogenous kinases. Lane 1 is a contr ol o f untransfected cell extracts. Lanes 2 
to 4 are derived from U 20S cells transfected with wild type pRb, 873/874RR and 873/874QQ 
(lOpg) respectively.
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Figure 3.11 Summary o f pRb acétylation.
Overall, the results suggest that E lA /p300 can positively stimulate pRb acétylation, and that the pRb 
associated HDAC activity may de-acetylate pRb (Smith et. al., personal communication). Acetylated pRb 
binds more efficiently to MDM2, and acétylation in the C-terminal region of pRb also affects its 
phosphorylation by cyclin/CDK complex. A possible unidentified cellular E lA -like activity could exist in 
regulating pRb acétylation. In addition, acétylation might have other function(s) in controlling pRb 
activity.
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Chapter 4: Functional Interaction of a Nucieosome Assembly 
Protein-2 and p300
/ntroduction
Transcription of the eukaryotic genome is a highly dynamic process in which genes are 
constantly turned on and off. Genomic DNA exists as chromatin, whose complex structure and 
highly condensed status acts as a significant barrier to sequence specific transcription factors by 
preventing them accessing and activating target genes (reviewed in 7, 54, 82, 157, 170). Until 
now, at least two mechanisms have been widely documented to remodel chromatin, thereby 
regulating tai'get genes transcription (reviewed in 82). The first mechanism involves enzymatic 
activities, such as acetylation/deacetylation, methylati on/ de-methy lation, and/or 
phosphorylation. In particulai*, HATs and HDACs, which, respectively, add and remove acetyl 
groups from the amino termini of the four core histones; hyperacetylation is usually (but not 
always) correlated with activation of transcription, whereas hypoacetylation is associated with 
repression of transcription. The second mechanism consists of ATPase-dependent chromatin 
remodelling complexes, which utilize energy from ATP hydrolysis to alter chi'omatin structure 
by changing the location and/or conformation of the nucleosomes.
The p300/CBP family is a group of co-activator proteins that act to nucleate the 
assembly of diverse co-factors into co-activator complexes (reviewed in 147). p300/CBP were 
shown to bind to a wide variety of transcription factors (55, 76, 87, 92, 97, 147, 164, 178), 
interact directly with the basal transcription machinery (124), and possess intrinsic HAT activity 
(12, 128). These proteins function as transcription co-activators through a process that is 
believed to bridge transcription factors with the basal transcription machinery, and by utilizing 
their HAT activity. The p300/CBP HAT domain can stimulate transcription when artificially
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tethered to the AdML promoter as a Gal4- fusion protein (109). However, evidence is still 
lacking that p300/CBP acetylates histones on promoters in vivo. p300/CBP has been frequently 
found in complexes with other HATs, including pCAF (188), SRC-1 (154) and ACTR (26). 
Different HATs may act on specific substrates to achieve a co-ordinated transcriptional 
programme. Alternatively, a critical mass of HAT activity maybe required to achieve 
transcriptional activation. In this model, p300/CBP might be considered as an assembly platform 
for the formation of protein complexes, leading to transcriptional activation. Furthermore, 
p300/CBP can acetylate other non-chiomosomal proteins, including TFIIE and TFIIF (68), 
which are part of the basal transcription machinery, suggesting alternative mechanisms of 
p300/CBP in transcriptional control.
Nucieosome assembly protein (NAP) is a family of histone chaperone-like proteins 
which have been attributed to roles in cell cycle function and transcriptional control (72, 79, 
171). Mouse NAP-1 (also known as AP-1) (70) was first cloned from FM3A cells using a 
biochemical assay to purify an activity which facilitates the assembly of nucleosome-like 
structures in vitro (70). NAP shai'es similar activity as nucleosplasmin and N1/N2 in its ability to 
bind to core histones, and induce supercoiling into DNA in the presence of histones (70, 71, 
171). Biochemical assays and immunoprécipitation experiments suggest that NAP preferentially 
binds to H2A/H2B heterodimer, and forms a 12S complex in the presence of the histone (71, 
112). Similar to nucleoplasmin and N1/N2, NAP family proteins also contain clusters of 
negatively charged amino acids, which might assist nucieosome assembly in vitro (49, 136). 
Soybean, yeast and Drosophila NAP-1 were demonstrated to possess nucieosome assembly 
activity (22, 49, 72, 191). Yeast NAP-1 stimulates transcription factor binding and histone 
displacement on a nucieosome template, probably via a mechanism involving disruption of the 
histone octamer (171). In Drosophila, dNAP co-operates with dCAF-1 {drosophila chromatin 
assembly factor-1 containing fraction) to promote regularly spaced nucieosome arrays in an
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ATP-dependent manner (22, 72). Interestingly, both yeast and Xenopus NAP-1 were shown to 
associate with Clb2 to perform Clb2-dependent mitotic functions, and suppress polar bud growth 
in budding yeast (79, 80). Human NAP-2 was identified by positional cloning at chromosomal 
location llp l5 .5 , a region implicated in several diseases including Wilms tumour (WT) and 
Beckwith-Wiedemann syndrome (BWS), in an effort to determine the genomic boundary for 
imprinting in the region (66, 136). However, hNAP-2 is biallelically expresssed, and was not 
found to be involved in the WT or BWS etiology (64, 134). NAP-2 shows significant sequence 
homology to NAP-1 and also possesses histone binding and nucieosome assembly activity (136). 
hNAP-2 is phosphorylated by Caesin kinase 2 (CKIl), and phosphorylated hNAP-2 is retained in 
the cytoplasm in a complex with histones during the GO/Gl phase. Dephosphorylation of NAP-2 
at the Gl/S boundary triggers NAP-2 transport into the nucleus in S phase, suggesting a role in 
replication-dependent chromatin assembly (137). Consistent with this finding, hNAP, yNAP and 
dNAP were predominantly cytoplasmic, but showed nuclear localisation during the S phase of 
the cell cycle (72, 137). Another NAP family protein, TAF-1 (template activating factor 1, also 
known as set), was identified on the basis of its ability to stimulate adenovirus replication in a 
viral chromatin template (123). In addition, TAF-1 is the subject of chromosomal aberration in 
myeloid leukaemiogeneisis (123), implying that the NAP family of proteins may play a role in 
oncogenesis. Overall, NAP is a family of proteins which are highly conserved through evolution 
among different species, with common function in histone binding and nucieosome assembly.
In an effort to understand p300 cellular functions, a yeast two-hybrid screen was carried 
out to isolate p300-interacting proteins (Shikama et. al., in press). Both NAP-1 and -2 
polypeptides were identified to bind to p300 from a lO.Sd.p.c mouse embryo cDNA library. 
Given that both NAP and p300 have been reported to act in chromatin remodelling and 
modification, experiments were carried out to investigate if these two proteins co-operate in 
transcriptional regulation. Domain mapping experiments suggested that NAP-2 binds
97
exclusively to the CH3 domain in p300. Conversely, p300 binds to two discrete regions in NAP, 
one in the central region, and the other in the C-tei*minal region. NAP family proteins may also 
dimerise and/or oligomerise in vitro. Domain-mapping experiments suggested that the N- and C- 
terminal of the protein is required for NAP-NAP interaction. Furthermore, NAP was found to 
augment the transcriptional activity of p300 targets, including p53 and E2F-1. Interestingly, 
NAP inhibits histone actylation by p300 in vitro, probably by binding directly to the histone 
tails. NAP was not found to have any intrinsic HAT activity, nor act as a substrate of acétylation 
by p300.
Results
Using LexA-p300^^^'^^^‘^ as bait, one NAP-1 and two NAP-2 clones were identified as 
p300 interacting proteins from a 10.5 d.p.c. mouse embryo cDNA library (Shikama et. a l, in 
press). Other p300 interacting proteins identified included JMY (146). Immunoprécipitation 
experiments were performed in which over-expressed G4-p300^^’'^ ®^'^  was confirmed to interact 
specifically with HA-NAP-2 in SA0S2 cells (Shikama et. a l, in press). Using an anti-NAP-2 
antibody against the C-terminus of the protein, it was demonstrated that endogenous NAP-2 
associated with p300 in A31 cells (Shikama et. a l, in press). The mouse NAP-2 protein was 
shown to possess nucieosome assembly activity using a DNA superc oiling assay (Cairns et. a l, 
personal communication). In addition, p300 augmented NAP-2 function in the supercoiiing 
assay.
The aim of this study was to define the domains of interaction between NAP-2 and 
p300, to decipher the functional significance of the interaction, and to explore the possible 
regulation of NAP-2 on p300 HAT activity. It is to be noted that two NAP-2 splice isoforms 
were isolated, named L5 and L7 (66, 136). L7 has additional 12 amino acids at the C-terminus of 
the protein (136). All work presented here used the NAP-2 L7 isoform (which is generally 
referred to as NAP-2), unless otherwise stated.
NAP-2 binds to the CH3 domain in p300
Original yeast two-hybrid screening experiments identified a p300 fragment from amino 
acid residue 611-2284 bound to NAP-2 (Shikama et. a l, in press). Mammalian two hybrid 
assays were performed to further locate the NAP-2 binding domain(s) on p300. Various Gal4- 
p300 fragments were tested for their binding to NAP2-VP16 (Fig 4.1b). The NAP-2 binding 
domain on p300 was mapped to the C-terminal region, from amino acid 1572-2284. The binding
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domain was further resolved to a region between 1572-1906, which encompasses the CH-3 (Fig 
4.1b). In the same experiment, Gal4-p300*®^ ®'^ ^®° and Gal4-p300^ °^*"'^ ^ '^^  were not found to 
interact with NAP-VP16.
In order to substantiate the mammalian two-hybrid mapping data, an alternate approach 
was used to confirm the result. Various GST-p300 fusion proteins were over-expressed and 
purified from bacterial extracts. The NAP-2 polypeptide was generated and labeled with by 
in vitro transcription and translation. An in vitro binding assay was performed to identify the 
NAP-2 interaction domain on p300. Consistent with the findings of the mammalian two-hybrid 
assay, GST-p300^^^ '^^^°  ^bound specifically to NAP-2, but not to lucifearse, which was used as a 
negative control for non-specific binding (Fig 4.2). Furthermore, two over-lapping fragments, 
GST-p300‘^ ‘^ -^ °^ ° and p300^^^ '^^^^\ did not bind to NAP-2 (Fig 4.2), nor did any other GST-p300 
fusion proteins which lack the CH3 domain. Some of the GST-p300 fusion proteins (e.g. 1-595, 
1818-2080, 1906-2284) were active in binding to other well-described p300-interacting proteins, 
such as p53 and E2F-1 (data not shown). GST-p300^^^ '^**'^ ,^ which encompasses the HAT 
domain of p300, has active HAT activity (Bandara et. a l, personal communication). Therefore, 
all GST-p300 fusion proteins are active in at least some p300 functions. Their lack of binding to 
NAP is not simply due to possible structural defects of the truncated proteins. These results 
indicated that NAP-2 bound specifically to the CH3 domain of p300.
Both the central and C-terminal region of NAP-2 bind to p300
Similarly, in vitro pulldown assays were used to identify p300 binding domain(s) on 
NAP-2. Various NAP-2 derivatives were ^^S-labeled by in vitro transcription and translation. 
Luciferase was used as negative control for non-specific binding. GST-p300^^^ '^^^°‘^ was used to 
pulldown different NAP-2 derivatives, and GST- alone was used as control for non-specific 
binding. Binding results suggested that NAP-2 has two discrete binding domains for p300, one
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in the central region from amino acid 110-230, and the other in the C-terminal region, 
encompassing amino acid 234-386 (Fig 4.3a, b and c). The N-terminal region from amino acid 
1-123 only had a marginal level of binding to p300, which was probably due to non-specific 
binding. These results indicated that NAP-2 contains at least two distinct interaction domains for 
p300.
The N and C-terminal regions of NAP-2 can mediate homo- or hetero- 
dimerisation of NAP family members
Previously, NAP-1 was found to sediment to a position of approximately 5S on a 
sucrose gradient, which has been considered as evidence for a dimer in physiological ionic 
condition (71). Experiments were therefore carried out to test if NAP-2 can form homo- or 
hetero- dimers. Using the biochemical pulldown approach, various NAP-2 deletion polypeptides 
were tested to identify the putative dimérisation domain(s) in vitro. His-NAP-2 fusion proteins 
were purified from bacteria (Fig 4.4a), His-beads treated with bacterial lysate which did not 
over-express His-NAP-2 fusion protein were used as a negative control for non-specific binding. 
The results suggested that NAP-2 can interact with itself under the conditions tested (Fig 4.3e, 
lane 1). Furthermore, there were two discrete domains for dimérisation, one in the N-terminal 
from amino acid 1-123, and the other at the C-terminal from amino acid 234-386. An internal 
region from amino acid 110-230 was not required for NAP-NAP interaction (Fig 4.3d, e and f). 
It was also demonstrated that NAP-1 can bind to NAP-2 using the same assays (Shikama et. a l, 
in press). Taken together, these results indicated NAP family members can form homo- and/or 
hetero-dimers, and two binding domains are likely to be involved in facilitating these 
interactions.
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NAP-2 inhibits p300-dependent histone acétylation
p300 is endowed with HAT activity, and acetylates all four core histones in vitro (12, 
128). At least on some promoters, the intrinsic HAT activity is required for its transcription 
activation (109). Here, experiments were earned out to investigate if NAP-2 regulates the p300- 
dependent acétylation. First, NAP was shown not to be a substrate of p300 or p300/pCAF HAT 
activity (Fig 4.4b). By titrating in the indicated amount of bacterially purified His-NAP-2 fusion 
protein (either L5 or L7), NAP-2 inhibited histone acétylation (Fig 4.5a). NAP-2 also inhibited 
histone acétylation by another HAT, namely pCAF (Fig 4.5b). Furthermore, although NAP-2 
inhibited histone acétylation by p300 in vitro, it did not inhibit the autoacetylation of p300, 
implying that NAP-2 might not affect the intrinsic HAT activity of p300 (Fig 4.5c).
NAP family of proteins aie known to bind to histones (71), possibly via the two highly 
conserved acidic amino acid regions (49). These acidic residues were thought to interact with the 
basic tail-region of histones, in a charge-mediated interaction (49). A synthetic peptide 
containing the acidic stretch in the C-terminal, but not a control peptide covering the N-terminal 
of the protein, was found to inhibit p300 and pCAF-dependent acétylation in vitro (Fig 4.5d). 
Together with the observation that GST-histone tail fusions can interact with NAP (Shikama et. 
a l. Smith et. a l, personal communication), it suggested that NAP-2 bound to histone tails, 
possibly ‘hiding’ the lysines in the tail region, and thereby inhibiting histone acétylation. 
Consistent with this idea, NAP-2 was also found to inhibit histone deacetylation by HDACs in 
vitro (Smith et. a l, personal communication).
NAP-2 and p300 co-operate in transcriptional activation
Since both NAP-2 and p300 were reported to possess chromatin remodelling activity in 
regulating transcription (171), experiments were performed to investigate if p300 and NAP-2 
regulate transcriptional activity. Using a reporter gene assay, p300 and NAP-2 were
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demonstrated to co-operate in transcription activation mediated by E2F-1 and p53 (Fig 4.6 and 
Shikama et. a l, in press). The reporter was stably integrated into U20S cells to recapitulate the 
chromatin environment. Gal4-E2F-F®° '^ ^^ , which contains the transcription activation domain of 
E2F-1 fused to the Gal-4 DNA binding domain, was used to activate the reporter. When NAP-2 
or p300 were transfected independently with Gal4-E2F-1, only marginal transcription co­
activation of 1.5-2 fold was observed. Co-transfection of all three constructs showed a 
significant co-activation of 8-9 folds over G4-E2F-F^°‘^ ^^  alone (Fig 4.6). Similar experiments 
also suggested that NAP and p300 augment p53 transcriptional response (Shikama et. a l, in 
press). Furthermore, this co-operation can be blocked by a dominant negative p300 construct 
from amino acid 1572-1906, which encompasses the NAP-2 interaction domain on p300. In 
addition, NAP/p300 co-operates in up-regulating endogenous p21 (47) gene transcription by p53 
in SAOS2 cells (Shikama et. a l, in press). These observations suggested that NAP-2 augments 
the transcriptional activity of at least two p300-dependent transcription factors.
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Discussion
In this study, NAP-2 was identified as a novel p300 interacting partner. Given that both 
proteins have chromatin re-modelling activity (82), effort was concentrated to elucidate the 
functional consequence of NAP and p300 in transcriptional regulation. Indeed, NAP and p300 
were found to augment E2F-1 and p53 dependent transcription activation. The result was 
substantiated with the observation that NAP-2 and p300 co-activated endogenous p21 gene 
expression in a p53-dependent manner (Shikama et. a l, in press). Previously, the p300/CBP 
family member p270 was found to be a component of the mammalian SWFSNF complexes (34). 
NAP was also demonstrated to co-operate with the ISWI-ATPase complex in generating spaced 
nucieosome arrays (22, 72). The interaction between NAP and p300 might reflect another 
mechanism of co-operativity between HAT and ATPase remodelling activity in transcriptional 
regulation.
Domain mapping experiments demonstrated that NAP-2 specifically interacts with the 
CH3 domain in p300. A variety of cellular factors, including E2F-1 (164) and p53 (55), and viral 
oncoproteins, such as E lA  (147), bind to p300 in similar region. Given that NAP augments E2F- 
1 and p53 transcription in a p300-dependent manner, it is unlikely that the NAP-p300 interaction 
will hinder the p300-E2F/p53 interaction. Indeed, E2F-1 and p53 may have multiple interaction 
domains within p300, including the CHI, CH3 and the C-terminal activation domain of 
p300 (data not shown). It will be interesting to investigate if NAP binding to p300 augments or 
alters the p300-E2F-l/p53 interaction, which could be another possible explanation to the 
activation observed with the E2F-1- and p53- dependent transcription.
p300 binds to at least two discrete regions on NAP-2. It is noted that both the central and 
the C-terminal domains in NAP-2, which were sufficient to bind to p300, possess stretches of 
highly conserved acidic amino acids. These acidic stretches may be important in mediating
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NAP-2-histone interaction. Further experimentation will be required to characterise the precise 
region mediating the NAP-2/p300 interaction. Interestingly, in the binding assay performed, 
NAP-2 was found to complex with NAP-1 and NAP-2, possibly forming homo- or hetero­
complexes with other family members. This is consistent with the previous observations 
suggesting that NAP protein might exist as dimer/oligomer under physiological conditions (71). 
When NAP was mixed with core histones, it sedimented as a 12S complex on a sucrose gradient 
(70, 71). The 12S complex was thought to consist of a histone octamer and two or three 
molecules of NAP (70). Two discrete regions were found to mediate dimer/oligomer formation, 
one in the N-terminal and the other in the C-terminal region of the protein.
In the current study, NAP-2/p300/histones were found to exist in a ternary complex 
(Shikama et. a l, in press). This was demonstrated by using an in vitro binding assay and by 
using a sucrose gradient. Furthermore, the NAP-2/p300 interaction was stabilized in the presence 
of histones. Therefore, NAP-2/p300 might form a tight complex with histones in the 
nucleosomes, which then stabilize clnomatin in an activated state for transcription activation. 
Experiments were carried out to address whether NAP-2 can interact with the nucieosome in a 
nucieosome gel-shift assay (data not shown). However, the evidence was not conclusive if NAP- 
2 is in a stable complex with the nucieosome.
From the immunoprécipitation study, a low level of NAP-2 protein was in complex with 
p300 (Shikama et. al., in press). Immunostaining experiments suggested that NAP-2 is 
predominantly cytoplasmic (72, 80, 136, 137). However, a significant amount of NAP re-located 
to the nucleus in S-phase, suggesting a role for NAP proteins in histone shuttling (72, 136, 137), 
and indicating a possible involvement in a replication-dependent nucieosome assembly. Indeed, 
the NAP family member TAF-1 was shown to activate adenoviral replication in a viral 
chromatin template (123). It remains to be tested if p300/NAP is involved in replication- 
dependent chromatin assembly. Interestingly, the NAP-2 protein was found to be phosphorylated
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in ceils and phosphorylation of NAP-2 may control its celluar localisation (137). CKII 
phosphorylates NAP-2 in HeLa and COS cells (137), and phosphorylated NAP-2 was retained in 
the cytoplasm. Consistent with the data, multiple consensus CKII phosphorylation sites do occur 
thi'oughout the NAP-2 protein sequence (136). In yeast, NAP was found to be associated with 
Clb2 (79), and can be phosphorylated by cyclin B/p34‘^‘^‘^  ^ in vitro (80). Furthermore, NAP is 
required for Clb-2 mediated mitotic functions, including microtubule re-organisation during 
mitosis, and to suppress polar growth of the budding yeast (80). yNAP also interact with another 
kinase, the Gin4 kinase (4). Overall, phosphorylation control of NAP possibly occurs in a cell 
cycle dependent manner. It will be important to establish if the NAP-p300 interaction is also 
regulated by phosphorylation. Since NAP-2 was found to facilitate nucieosome assembly and 
co-operate with p300 in transcriptional regulation, both functions may require NAP protein to 
localise to the nucleus. NAP is only transiently transported into the nucleus during S phase of the 
cell cycle, and NAP predominantly resides in the cytoplasm. This potentially offers an 
explanation of low level of interaction between NAP-2 and p300 in various immunoprécipitation 
experiments performed by my colleagues in the laboratory.
Since the intrinsic HAT activity is important for p300-dependent transcription co­
activation (109), experiments were carried out to investigate if NAP regulates p300 HAT 
activity. First, NAP was demonstrated to possess undetectable HAT activity. In addition, NAP 
was not acetylated by p300 or pCAF in vitro. However, NAP inhibits histone acétylation by both 
p300 and pCAF in vitro. A synthetic peptide encompassing the C-terminal acidic stretch also 
inhibits histone acétylation in vitro. This observation at first seems to contradict with the 
findings that NAP/p300 co-operates in transcriptional activation since hypoacetylation of 
histones is generally correlated with transcriptional repression. Further analysis suggested that 
NAP does not inhibit the intrinsic HAT activity of p300. Indeed, NAP was known to bind to 
both acetylated and unacetylated histones with similar efficiency (112). The acidic amino acids
1 0 6
were shown to be required for histone binding (49). Therefore, the most likely explanation is that 
NAP binds to the N-terminal tail of histones, possibly via a charge-charge type of interaction, 
thereby ‘hiding’ the lysines in the histone tail from p300/pCAF HAT activity. The significance 
of this inhibition in term of NAP/p300-mediated transcriptional regulation is not clear.
In conclusion, p300 associates with a class of transcription regulator, NAP, which can 
contribute to chromatin remodelling. Here, p300 and NAP were demonstrated to activate 
transcription. Whilst it is well established that the HAT activity of p300 is required for 
transcriptional activation, at least on some promoters (109), the underlying mechanisms 
responsible for these effects are not clear. Moreover, while both ATP-dependent chromatin 
remodelling activity and HAT activity are known to be important for transcription regulation, the 
order in which these activities act on promoters is unclear. The current idea (82) is that the 
ATPase activity acts first, which causes a rapid interconversion of chromatin between an 
activated and a repressed state. The HAT activity is then targeted to the activated gene to ‘fix’ 
the chromatin in the active state to substantiate its activation. Although the generality of this 
model remains to be tested, our observations provide one mean to bridge together the ATPase 
activity with HAT, most probably via a direct interaction between NAP and p300 (Fig 4.7). NAP 
function is cell cycle regulated (112, 157), as well as the apparent association with H2A and 
H2B (71), indicating a histone chaperone function in transporting histones from the cytoplasm to 
nucleus. In the nucleus, NAP may act in concert with ATPase-dependent remodelling factors to 
re-structure nucieosome positioning. It may not be a coincidence that NAP interacts with the 
histone tails and the disordered regions of linker histone (112), since these are regions subject to 
post-translational modifications such as acétylation and the sites of action for transcriptional 
activators. Therefore, one might imagine that NAP recruits p300 to certain activated 
nucleosomes, allowing p300 to target specific nucleosomes to achieve a regulated transcriptional 
co-activation.
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Figure 4.1
NAP-2 binds to the CH3 domain in p300.
a) Summary of functional domains and sequence similarity between NAP-1 and NAP-2. Mouse 
NAP-1 and NAP-2 share extensive homology. The numbers indicate the percentage of identify 
among the three shaded regions. Two stretches of acidic amino acids, one in the central region, 
and the other in the C-terminus of the protein, are indicated in red. A putative nuclear localisation 
signal (IKKKQKH) is indicated in blue.
b) A mammalian two-hybrid assay was performed in U 20S cells. The schematic representation of 
the assay is indicated in i). In ii), iii), iv) and v) pG4-p300‘^ ^^ '^ ®^'^ , pG4-p300^^^^'*^^^, pG4-
and pG4-p300^®*®'^°^° were tested if they interact with pVP16-NAP-2. Lane 1 is the 
basal activity of the reporter alone. Lanes 2 to 4 are controls when pG4 (Ipg) was co-transfected 
with pVP-16, pVP-16-NAP-2, or non-specific DNA (all 0.5p.g). Lanes 5 and 7 are controls when 
the indicated pG4-p300 derivatives (IjAg) was co-transfected with pVP-16 or non-specific DNA 
(0.5p,g). Lane 6 shows activity when the indicated pG4-p300 derivative was co-transfected with 
pVP-16-NAP-2 (0.5jig). The values shown are derived from duplicate readings (luciferase/(3-gaI 
activity). All experiments have been repeated at least three times to ensure the reproducibility. 
Similar results have been reproduced in C33A cells.
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Figure 4.2
NAP-2 binds to the CH3 domain in p300.
a) Binding assay between the indicated GST-p300 fusion proteins and in vitro translated NAP-2 
(top panel) or luciferase (bottom panel) in which about 5 jUg o f GST-fusion proteins was 
incubated with the in vitro translated products. The luciferase was used as a negative control for 
non-specific binding to the GST-fusion proteins.
b) Summary of the binding data in a). NAP-2 binds exclusively to the CH3 domain in p300, from 
amino acid 1737-1818.
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Figure 4.3
Domains in NAP-2 interact with p300, and NAP-2 oligomerisation domains.
a), b) and c) The indicated regions of NAP-2 were in vitro translated as shown in a) and assessed for
binding to (about 5|4g) shown in b), or GST alone (about S^ig) shown
in c).
d), e) and f) The indicated regions of NAP-2 were in vitro translated as shown in d) and assessed for
binding to His-NAP-2 (about 5pg) shown in e) or His-control beads shown in f).
g) Summary of the binding domains in NAP-2 for p300 and NAP-2 protein.
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Figure 4.4
NAP is not acetylated in vitro.
a) Coomassie stain of His-NAP2 (L5 and L7) purified from bacteria.
b) The left panel shows an autoradiograph where histone is acetylated by p300 and a combination of 
p300 and pCAF. H3 and H4 are preferentially acetylated compare to H2A and H2B. The right 
panel shows an autoradiograph where NAP was tested as a substrate for acétylation in vitro, using 
either p300 or p300 and pCAF as the enzyme source.
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Figure 4.5
NAP-2 inhibits histone acétylation by p300 in vitro.
a) Both NAP-2 (L5) and (L7) isoforms inhibit histone acétylation by p300 in vitro. L5 and L7
fusion protein were purified from bacteria as His-tagged fusion. 2p.g o f chicken histones were 
acetylated by 0.5 pg of Flag-p300^^35-24i4 ^ standard 30pl acétylation reaction. The x-axis
shows different units of L5 or L7 titrated into the reaction, with each unit represent 200ng of 
purified protein quantified by Bradford assay.
b) NAP-2 inhibits histones acétylation by pCAF. The assay is the same as described in a), but used 
Flag-pCAF as HAT source.
c) NAP-2 (L7) inhibits histone acétylation by p300 in vitro, but does not inhibit p300 
autoacetylation in the same assay. The experiment was carried out in the same way as described 
in a). However, instead of using filter assays to quantify the acétylation level, a SDS-PAGE gel 
was used to analyze the samples, and the proteins acetylated was labelled with and visualized 
after autoradiography. NAP or BSA (in control reaction) was titrated into the reaction (0, 0.25, 
0.5 and Ipg).
d) A NAP-2 peptide at the C-terminal region of the protein inhibits histone acétylation by p300 in 
vitro. A standard histone acétylation reaction was carried out as described in a). The basal level 
of acétylation is shown in lane 1. Lanes 2 to 4 show a titration (1, 2.5, 5pg) of a NAP-2 N- 
terminus peptide (142), which does not inhibit histone acétylation. Lanes 5-7 shows a titration of 
the NAP-2 C-terminal peptide (141) which shows significant inhibition of histone acétylation at 5 
Kg-
e) Lanes 1-3, 4-6, 7-9, 10-12 show a titration of 141, 142, Rb, and Histone H4 peptide (1, 2.5 and 
5pg) respectively. Lane 13 shows the background level of dpm from the scintillation assay. Both 
141 and 142 peptides show no significant level of acétylation. The pRb peptide (see chapter 3) 
shows a moderate level of acétylation. The peptide from the histone H4 tail was used as positive 
control for the acétylation reaction.
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Figure 4.6
NAP-2 augments the p300-dependent transcription factor E2F-1.
a) Graphical representation of the reporter construct used in the assay. This reporter was integrated 
into the U 20S cells to recapitulate the chromatin environment of the genome.
b) The reporter was activated with the expression vector pG4-E2F-l^®^''^^^ (lOOng). Co-transfection 
with 5|ig of pHA-NAP-2 (L5) or (L7), or 5|u.g of pCMV-p300 only caused marginal co-activation 
over pG4-E2F-l^®°''’^ ’ . However, co-transfection of all three plasmids together showed significant 
augmentation of the E2F-1 mediated activation of the reporter. The Y-axis shows the average 
value of duplicate readings and represents the normailised level of luciferase/P-galactosidase 
activity.
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Figure 4.7 A  hypothetical model o f p300 and NAP co-operate in transcriptional regulation.
A hypothetical model o f ATP-dependent remodelling and acétylation as regulators of chromatin fluidity 
(reviewed in 82). In short, ATP-dependent remodelling complexes are suggested to increase the rate of 
interconversion between different chromatin states. In this case, NAP might co-operate with ISWI-related 
chromatin remodelling complexes to facilitate the switch of different chromatin configurations. Activating 
complexes and HATs are proposed to be recruited and preferentially bind to the activated states of the 
chromatin, and therefore ‘fix’ the chromatin configuration in an activating status. NAP may play a role in 
‘directing’ p300 activity to ‘fix’ the chromatin configuration, possibly through its ability to physically 
interact with p300. This process leads to the transcriptional co-activation, as observed for the effect of 
NAP and p300 on p53 and E2F-1.
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Chapter 5: Mutagenesis of the pRb pocket reveals that the cell 
cycle arrest function are separable from LXGXE 
binding
Introduction
The retinoblastoma protein (pRb) regulates the G 1/S transition in the cell cycle 
(reviewed in 43, 175). The regulation of E2F-dependent transcription is thought to be an 
important aspect of pRb’s function in cell cycle control (reviewed in 43, 62, 91). Previous 
studies have indicated that pRb has multiple modes in regulating E2F transcription (43). First, 
pRb binds to the rran^activation domain of E2F, blocking its interaction with the basal 
transcription machinery. Second, it is increasingly apparent that E2F binding sites mediate 
transcriptional repression (30, 162, 171, 199). For example, B-myb, E2F-1 and pl07 promoters 
possess repressive E2F sites whose occupancy co-relates with transcriptional repression 
(reviewed in 43, and references therein). In this respect, it is likely that the pRb family members 
play an important role not only in down-regulating E2F-dependent transcription by excluding the 
rran^activation domain, but also in facilitating E2F- dependent transcriptional repression by 
assembling active repressive complexes with E2F.
The pocket domain of pRb was originally identifed as the region required for binding to 
viral oncoproteins. When the pRb pocket was artificially tethered to the promoter region as a 
Gal4- fusion, it repressed transcription, indicating its intrinsic transcription repressive activity 
(30, 177). Molecular candidates which could account for this active repressive function include 
CtIP (113), HBPl (159), HDACs (19, 103, 106), and hSWFSNF (196), which are all known to
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bind to pRb in a pocket dependent manner. In particular, HDACs and h-SWl/SNF are classes of 
proteins with chromatin remodelling activity (60, 82). Upon treatment with trichostatin A (TSA), 
which is a deacetylase inhibitor (103), repression on Cyclin E and E2F-1 promoters is relieved 
(103). However, this effect is promoter dependent, as the repression on the TK and B-myb 
promoters is not relieved after TSA treatment. More recently, a pRb-HDAC-hSWFSNF trimeric 
complex was demonstiated, and was shown to repress cyclins E and A gene tianscription, 
arresting cells in the G1 phase of the cell cycle (196). Phosphorylation of pRb by cyclinD/cdk4 
disrupts pRb/HDAC association, but the pRb-hSWFSNF complex persists to repress the cyclin 
A gene transcription and prevent cell cycle progression beyond S phase (196). Therefore, a 
model was proposed that different pRb-associated repressive complexes maintain the order of 
expression of different sets of genes during the cell cycle, which in turn regulates exit from G1 
and from S phase respectively. This might also explain the selective effect of TSA on different 
promoters.
HDACs, hSWI/SWF, CtIP and HBPl all share a conserved LXCXE peptide motif, 
which was thought to be important in binding to pRb. Three dimensional structural analysis of 
the pRb pocket in complex with the LXCXE peptide from E7 oncoprotein illustrates that the 
LXCXE peptide binds to a conserved groove in the B box of the pocket (94). This LXCXE 
binding site is highly conserved among pRb homologs from different species, and is also 
conserved among family members pl07 and pl30 (94). E2F, on the other hand, binds to a more 
promiscuous region which is non-overlapping with the LXCXE peptide binding site (94). 
Consistently, biochemical evidence exists that E2F/pRb/HDAC ternary complex is stable (19). 
Interestingly, unlike viral oncoproteins such as E lA  or E7, many cellular factors may not rely 
heavily on the LXCXE motif for binding to pRb (38). Mutation of the LXCXE binding pocket 
disrupts viral oncoprotein binding, whilst most of the cellular factors containing the LXCXE 
motif still interact with pRb (38). Furthermore, cyclin D/cdk4 disrupts pRb-HDAC interaction.
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but fails to affect pRb-hSWI/SNF interaction, suggesting cellular factors use multiple surfaces 
for interaction with pRb, which also reflects the complexity of the regulation of pRb binding to 
target molecules (196).
In this study, I have investigated the consequences of mutating the LXCXE-binding 
motif in pRb. One such mutant is significantly compromised in binding to HDAC and other 
LXCXE-motif containing proteins, but is capable of binding to other targets, such as E2F and 
TAFii250, which bind to pRb in a LXCXE-independent manner. Interestingly, this mutant can 
arrest SA0S2 cells in the G1 phase upon over-expression. Therefore, it suggested that HDAC 
maybe dispensable for pRb mediated G1 arrest.
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Results
Mutational analysis of a conserved lysine patch in B domain of pRb
Originally, the investigation was focused on possible lysine residues which might be 
subject to acétylation in the B pocket domain. Sequence comparison among pRb family 
members and homologues from different species identified a group of highly conserved lysine 
residues in the B pocket of pRb (Fig 5.1c, d and e). The three dimensional structure of the small 
pocket domain of pRb bind to the LXCXE-containing peptide indicated that these lysines scatter 
around the LXCXE-binding groove (Fig 5. le), and might function in recognising the LXCXE- 
peptide (94). In particular, K713 and K765 make contact with the backbone of the LXCXE 
peptide (94). K720, K722, K729 and K740 might contribute a cloud of positive charges which 
could facilitate LXCXE-peptide motif-containing proteins to bind to pRb (94). Acidic amino 
acid residues aie frequently found to flank the LXCXE sequences (Fig 5. If). Systematic site- 
directed mutagenesis was carried out until all the six lysines residues were changed to alanine 
(Fig 5.1a). Since all the lysine residues were on the surface of the protein (94), the change to 
alanine was predicted not to cause diamatic conformational change of the pRb molecule. All 
mutants were expressed to similar level as wild type pRb in various cell lines (Fig 5.1b and data 
not shown). As mentioned in chapter 3, K713 was found to be acetylated in a synthetic peptide 
(see chapter 3).
The pRb 6A mutant is compromised in binding to LXCXE-motif containing 
proteins
Given that these lysine residues might function in recognising the LXCXE-peptide 
motif, biochemical pulldown assays were performed to test if the mutants were compromised in 
binding to LXCXE-motif containing molecules. The wild type pRb and the less severe mutants
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( lA l and 2A) efficiently bound to E7 and cyclin D (Fig 5.2 c iv) and v)). The binding to cyclin 
D was much less efficient than to E7, indicating pRb/cyclin D interaction is a low affinity event. 
The pRb 6A mutant was significantly compromised in binding to both E7 and cyclin D (Fig 5.2c 
iv) and v)). When the binding of pRb and mutants with E2F-1 was analysed, all mutants 
progressively lost affinity in binding to E2F-1. However, pRb 6A still maintains significant 
affinity in binding to E2F-1 (Fig 5.2c iii)). Since E7 and cyclin D contain the LXCXE motif, this 
suggested that pRb 6A is compromised in interacting with the LXCXE-motif containing protein. 
Furthermore, pRb 6A completely lost ability in binding to HDAC (Fig 5.2b). HDAC was known 
to contain an LXCXE like motif, which was thought to be important in mediating its interaction 
with pRb, Consistently, pRb lA l, which is capable in binding to the LXCXE-peptide motif, 
retained efficient binding to HDAC (Fig 5.2b). Similarly, pRb 6A  was found to have reduced 
affinity in binding to E2F-1 when GST-pRb 6A and in vitro transcribed and translated E2F-1 
was used in the pulldown assay (Fig 5.2b). TAFn250, which is another molecule which binds to 
pRb in an LxCxE-independent manner (144), was found to interact with pRb and mutants in a 
similar manner as E2F-1 (Fig 5.2b). Whilst the mutants progressively lost affinity in binding to 
TAFii250, pRb 6A still retain significant affinity to bind to TAFu250.
The pRb 6A represses E2F-1 transcription
The most important properties of pRb’s tumour suppressive function were attributed to 
its ability to repress transcription from E2F-family proteins (reviewed in 43). Therefore, 
experiments were carried out to investigate if pRb mutants inhibit E2F-dependent transcription. 
All pRb mutants tested repressed E2F-1 mediated transcription (Fig 5.3c and data not shown). 
Similar repression was observed from the cyclin E-luc reporter (Fig 5.3c), and from an artificial 
E2F-luc reporter (data not shown). Furthermore, these observations were repeated with different 
cell lines, including C33A, U20S and SAOS2 (Fig 5.3c and data not shown). In nearly in all
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cases, mutants behaved similarly as the wild-type pRb in repressing E2F dependent transcrption. 
Since all the mutants were shown to retain ability to bind E2F, it was expected that they would 
repress E2F-dependent transcription. The pRb 6A mutant, which showed reduced affinity in 
binding to E2F-1, did consistently show slightly decreased efficiency in repressing E2F-1 
transcription.
Given pRb’s intrinsic transcriptional repressive ability is also relevant toward its growth 
suppressive function (177), a few representative mutants were fused to the Gal4-DNA binding 
domain and tested for their transcriptional repressor function. A Gal4-Tk-luc reporter and a 
Gal4-AdML-luc reporter were used in the assay (Fig 5.3 a and b). The Gal4-AdML-luc reporter 
was known to be TSA sensitive (103), indicating its regulation could be HDAC dependent. Both 
wild-type pRb and the pRb lA l mutant showed potent repressive activity. However, the intrinsic 
pRb repressive function was progressively lost with progressive mutation of lysine residues (Fig 
5.3 a and b). The Gal4-pRb 6A mutant showed much reduced ability in transcriptional 
repression.
The pRb 6A induces G1 arrest in SAOS2 cells
Over-expression of pRb in a Rb-deficient osteosarcoma cell line SAOS2, was known to 
cause G1 arrest. Here, I investigated if the pRb 6A mutant retains such function. The cell cycle 
profile was monitored by the use of a CD20 cell surface marker to identify the transfected cells. 
In these experiments, transient expression of pRb and pRb 6A gave robust cell cycle aiTest (Fig 
5.4). The pRb 6A was even slightly more efficient than the wild-type pRb in mediating G1 arrest 
in those experiments. Overall, it demonstrated that mutation of the lysine patch has no effect on 
pRb’s ability in mediating G1 arrest.
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Discussion
The pRb protein is a master regulator of cell proliferation, differentiation and survival. A 
detailed structure-function analysis on pRb was complicated since many of its functional 
properties rely on the integrity of its pocket domain, which is a structure difficult to analyse by 
systematic mutagenesis. The recently published pRb structure shows an extensive interface 
between the A and B halves of the pocket, and a highly conserved groove in binding to LXCXE- 
peptide (94). A number of important amino acid residues were indicated to function in 
contacting the LXCXE-peptide. In particular, a patch of highly conserved lysine residues was 
found to circumvent the LXCXE-peptide binding groove, suggesting possible functional 
importance.
Whilst our initial investigation focused on these lysine as possible sites of acétylation 
(also see chapter 3), subsequent analysis has not yet resolved the question of their possible 
modification by acétylation. However, one of these mutants, pRb 6A, was compromised in 
binding to HDAC, therefore allowed a separate investigation on the functional importance of the 
reported pRb/HDAC interaction (19, 103, 106).
Most of pRb’s tumour suppressive effect was ascribed to its ability to repress E2F- 
dependent transcription (43). Furthermore, pRb possesses intrinsic transcriptional repression 
activity (30, 177), which might involve its interaction with classes of molecules with chromatin 
remodelling activity, including HDACs and hSWFSNF complexes (19, 103, 106, 196). In 
particular, HDACs were reported to associate with pRb and E2F-1 in a trimeric complex, and 
selectively repress certain E2F-responsive promoters. Subsequently, it was suggested that 
HDACs are required for the pRb active repressive complex to repress certain genes during G 1/S 
transition, and contributes towards pRb’s G1 arrest function.
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A large number of pRb interacting molecules, including HDACs and hSWI/SNF, 
contain a motif known as the LXCXE, which was thought to be important in mediating the 
interaction (38). Mutational analysis of the pRb LXCXE-peptide binding groove showed that 
mutations in this domain are sufficient to block virus proteins, such as E7 and ElA, binding to 
pRb (38). This suggests viral oncoproteins heavily rely on this motif to bind to pRb and 
inactivate its function. Interestingly, most of the cellular factors seem not to be affected by these 
mutations, suggesting cellular factors may use multiple modes to bind to pRb, and the LXCXE is 
not the sole determinant for their interaction with pRb. Therefore, those pRb mutants were still 
capable of causing G1 arrest (38).
The conserved lysine patch is scattered around the LXCXE-binding groove. From the 
three dimensional structural studies, at least three functions were described to these lysines (94). 
First, K713 and K765 were found to directly contact the LXCXE-peptide backbone. Second, the 
other four lysines, including K720, K722, K729 and K740 were suggested to form an overall 
positive charge, which might ‘guide’ the LXCXE peptide into its binding groove. Indeed, most 
of the LXCXE-motif containing proteins have conserved acidic amino acids flanking the 
LXCXE sequence, which might interact with the highly positively charged lysine. Third, these 
lysine residues may function as phospho-receptor sites, and mediate intramolecular interaction 
when pRb is phosphorylated. One report demonstrates that phosphorylation at the C-terminal 
region of pRb initiates an interaction with this lysine patch, which subsequently leads to 
inactivation of pRb activity (59).
In this study, the most severe mutant, pRb 6A, was found to be significantly 
compromised in binding to various LXCXE-motif containing proteins, including E7, cyclin D 
and HDAC. However, this mutant still retains binding to E2F-1 and TAFn250, though with 
slightly decreased affinity. While pRb 6A is sufficient to repress E2F-1 transcription, it is 
significantly compromised in the intrinsic repression activity when tethered to the promoters as a
130
Gal4-fusion. One of the explanations is that the loss of binding to HDAC compromises its 
intrinsic repressive activity. However, other explanations also exist. It has yet to be tested if this 
mutant binds to hSWI/SNF complexes, which is another mechanism of pRb’s intrinsic 
repressive activity. Furthermore, as demonstrated by Dick et. at. (38), various pRb mutants 
which were compromised in LXCXE binding, while retaining HDAC binding, also showed 
similarly reduced repressive activity when assessed as a Gal4 fusion. The underlying mechanism 
was not investigated.
Nonetheless, the pRb 6A mutant is clearly defective in binding to HDACs and I tested if 
this mutant can cause G1 arrest. Previously, using the E2F DNA binding domain as a dominant 
negative to inhibit E2F-dependent transcription, it was shown that this was not sufficient to 
initiate several kinds of G1 arrest (197). Therefore, the active repressive complexes of E2F/pRb 
might contribute other functions for the G1 arrest. One of the candidates may be HDAC as it was 
shown to repress some E2F responsive genes required for Gl/S phase transition (196). However, 
over-expression of pRb 6A, which lacks the ability to bind to HDAC, maintains potent G1 arrest 
ability. This leads to the possibility that HDAC is not essential for pRb mediated G1 arrest, at 
least in SAOS2 cells under over-expression condition. An alternate explanation could be that 
under pver-expression conditions, pRb was expressed at an abnormally high level which might 
sequester other factors, thereby bypassing the need for HDAC. In a parallel study, HDAC or the 
pRb pocket domain was fused to the E2F-1 DNA binding domain, thereby artificially recruiting 
HDAC or pRb to the E2F-DNA binding sites (Smith et. a l, personal communication). Whilst 
the E2F/pRb hybrid was capable of mediating G1 arrest, the E2F/HDAC hybrid was deficient 
for such activity. Taken together, it suggests that HDAC may not be required for pRb mediated 
G1 aiTest. It is possible that HDAC is specifically involved in certain forms of G1 aiTest 
mediated by pRb. It also remains to be tested if HDAC is involved in other aspects of pRb 
function, such as pRb’s role during differentiation and anti-apoptosis.
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Figure 5.1 Mutagenesis o f pRb B pocket lysine residues.
a) Designated mutants nomenclature is listed, accompanied by the corresponding changes that have 
been introduced into pRb.
b) An immunoblot showing all mutants were expressed to similar levels in 293 HEK cells. lOpg of 
pCDNA3-9E10 pRb and mutants were introduced into 293 HEK cells and lOOpg of the total cell 
extracts were used for the immunoblot. The band corresponding to pRb were indicated with an 
arrow. (*) indicates a non-specific band which occur in all samples.
c) An alignment of pRb B pocket sequences from various species. Lysine residues which were 
mutated, were highly conserved among different species and they are indicated in red.
d) An alignment of pRb B pocket sequences from the three family members. The most conserved 
K713 is indicated in red. K720, K722 which show conservation in overall charge among the 
family members, are indicated in orange. The other three lysines, K729, 740, 765 are not 
conserved among the family members, are indicated in blue.
e) A diagram of an LXCXE peptide derived from E7 bound to pRb. This diagram is generated with 
Rasmol software using the co-ordinates as published (94). All lysines being mutated in the study 
and the LXCXE peptide are indicated. K713, 765 (blue) were reported to contact LXCXE peptide 
backbone. All other lysine that clusters around the LXCXE binding groove is shown in red.
f) Sequence alignment of LXCXE-containing proteins. The LXCXE motif was boxed in green. 
Various acidic amino acids flanking the LXCXE motif are indicated in blue.
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Figure 5.2 pRb 6A mutant has significantly reduced ability in binding to LXCXE-motif containing
proteins.
a) Coomassie blue staining of the purified GST, and GST-pRb and mutant recombinant proteins.
b) 5pg of the indicated GST-fusion proteins were used in the pulldown assay for HDAC2 (top 
panel), TAFn250 (middle panel) and E2F-1 (bottom panel) respectively. For HDAC2 and E2F-1 
pulldown, each indicated GST fusion protein was incubated with Im g of HELA nuclear extract, 
followed by immunobloting with the respective antibodies. For the TAFn250 pulldown, each 
indicated GST fusion protein was incubated with 200|Lig of sf9 cell extract which have over­
expressed HA-tagged TAFn250, using a baculovirus. Subsequently, the samples were analysed 
by western blot using anti-HA antibody.
c) Analysis o f pRb and mutants binding to E2F-1, cyclin D and E7.
i) pRb and the indicated mutants, and the luciferase were generated by in vitro 
transcription and translation. They were labelled with ^^S. This autoradiograph showed 
all proteins were generated to similar level for the experiment.
ii) GST (5pg) alone were used as negative control for the pulldown assay. No pRb or any 
mutants, or the luciferase were found to associated with GST fusion protein (top panel). 
The bottom panel show GST protein level (coomassie stained) used in the assay.
iii) GST-E2F-1 (5|ig) was used to pulldown pRb and the mutants. The top panel shows a 
long exposure of the autoradiograph (4 days). The middle panel shows a short exposure 
of the same autoradiograph (12 hours). The bottom panel shows the GST-E2F-1 protein 
level (coomassie stained) used in the assay.
iv) GST-E7 (5pg) was used to pulldown pRb and the mutants. The top panel shows a long 
exposure of the autoradiograph (4 days). The middle panel shows a short exposure of 
the same autoradiograph (12 hours). The bottom panel shows the GST-E7 protein level 
(coomassie stained) used in the assay.
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v) GST-cyclin D (5ju,g) was used to pulldown pRb and the mutants. The top panel shows a 
long exposure of the autoradiograph (4 days). The bottom panel shows the GST-cyclin 
D protein level (coomassie stained) used in the assay.
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Figure 5.3
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Figure 5.3 Transcriptional repression mediated by pRb and the mutants.
a) 10p.g of the indicated G4- and G4-pRb and mutants constructs were transfected into C33A and 
SA 0S2 cells respectively. The unrepressed state of Ijig of the Gal4-AdML-luc reporter was 
normalised to 100% of luciferase activity.
b) Same transfection condition was used as described in a). In this case, the repression on a Gal4- 
Tk-luc reporter was analysed using G4-Rb and mutants.
c) ljuig of cyclin E-Iuc was transfected into C33A cells. The reporter was activated upon co­
transfection of lOOng of pCM V-E2F-l. The repressive effect o f pRb and mutants on E2F-1 
mediated transcription was analysed by co-transfection of the corresponding expression vector as 
indciated (lOjlg each). The normalised activity of (luc/p-gal) of E2F-1 alone was normalised as 
100% of luciferase activity.
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Figure 5.4 pRb and pRb 6A arrest SA 0S2 cells in G1 phase of the cell cycle.
SA 0S2 cells were transfected with 10p,g of pRb or pRb 6A constructs, together with 10p.g of 
pCMV-CD20. Cells were fixed and stained for CD20 with fluorescein-conjugated antibody, and for DNA 
content with propidium iodide. The percentage of change of the cells (compare to a mock sample which 
were transfected with lOfig of pCDNA3 alone) in different phases of the cell cycle were shown in the 
diagram.
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Chapter 6: Summary 
Acétylation: more than the chromosome
The isolation of proteins with nuclear HAT activity is a key step forward in 
understanding the regulatory role of nucleosomes in transcription (reviewed in 21, 82, 170 and 
references therein). Although the connection between histone acétylation and transcription was 
observed at least 30 years ago, the enzymes responsible for such action remained elusive for a 
long time. Acétylation of multiple sites in the core histone tails was known to associate with 
transcriptional activity in isolated nuclei and partially purified chromatin preparations. 
Constitutively inactive heterochromatin shows a lack of acétylation in histone tails, suggesting 
deacetylation is linked with gene silencing. Substitution of the lysine residues in the H4 tail with 
arginine, which cannot be acetylated, virtually abolishes transcription of inducible genes in 
yeast. Conversely, substitution of the lysines with glutamate, which might mimic the acetylated 
state of lysine, can bypass the need for acétylation. When the first few nuclear HATs were 
identified, it was very encouraging that many of them were previously identified transcriptional 
regulators. Immediately, one question arises as to why there are so many HATs if their sole role 
is to modify nucleosomes.
So far, HATs can be divided into two groups: the type A HATs, which are nuclear, and 
active on chromosomal histones, with a role in transcriptional control; and type B HATs, which 
are cytoplasmic, and mainly acetyl ate newly synthesised histones. The nuclear HATs can be 
further divided into sub-families exemplified by pCAF/GCN5 (188), p300/CBP (12, 128), 
TAFii250 (116), SRC-1 (154) and MOZ (147). These sub-families of HATs show very low 
levels of sequence homomology, and were frequently found to interact with each other in multi­
protein complexes (reviewed in 52). Therefore, another question is why multiple HATs are
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needed in co-activator complexes. Part of the answer could be that the HATs may act on non­
histone targets. Indeed, a growing list of factors involved in transcription, including p53 (56), 
E2F-1, -2, -3 (110, 111), EKLF (195), GATA-1(17), HlV-Tat (78), MyoD (132), HNF4 (153), c- 
Myb (161), TFllE, TFllF (68) and HMGI(Y) (121) were found to be acetylated by p300/pCAF. 
Furthermore, proteins involved in other cellulai' processes, such as nuclear transport (e.g. 
importin-a family protein) (13), and microtubule organisation (e.g. a-tubilin) were acetylated 
too. Most of the HATs contain a homologous region known as the bromodomain, which was 
recently shown to recognise acetylated peptide motif (39, 74). Therefore, the presence of 
multiple HATs may function to recognise certain acetylated pattern on nucleosomes or protein 
complexes.
In this thesis, 1 reported pRb, and its family member pl07, which are well known 
tumour suppressors, are acetylated by p300, but not by pCAF. This also demonstrated the 
specificity of the enzymes for substrate modification. Unlike most of the other factors which 
were reported to be acetylated (such as p53, E2F, MyoD, c-Myb, and GATA-1), pRb is not a 
DNA-binding factor, but a pleiotropic transcription regulator, with ability both to activate and 
repress transcription (reviewed in 18, 120). A further complexity arises when multiple domains 
on pRb can be acetylated. Acétylation of pRb is dependent upon the integrity of its pocket, as 
various tumour-derived pRb mutants, such as A21, A22, and 706F mutants (chapter 3 and data 
not shown), had diminished level of acétylation. Using an extensive panel of GST-pRb 
derivatives, two discrete regions in the C-terminal region, and the A domain of the protein, were 
found to he acetylated. In particular, the C-terminal region is heavily acetylated. Since these 
regions are intact in the pRb tumour-derived mutants mentioned above, and invariably all the 
mutants were known to have altered conformation, these results in turn suggested that 
acétylation of pRb could be dependent on its proper folding.
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Nearly all the transcription factors known to he acetylated show enhanced DNA binding 
activity upon acétylation (17, 36, 110, 111, 132, 195). This is consistent with the view that 
acétylation is stimulatory towards transcription. In the case of p53, acétylation at the C-terminus 
might cause a conformation change in the protein, thereby relieving an inhibitory interaction 
between the C-terminus and the DNA binding domain (56). The underlying mechanism of the 
enhanced DNA binding for other factors was not investigated. Acétylation can also regulate 
protein-protein interactions. For example, acetylated dTCF had reduced affinity in binding to 
armadillo (172), and acetylated ACTR is inhibited to associate with nuclear receptors (52). 
These are unusual cases where acétylation is inhibitory to transcription. In this thesis, 1 reported 
that acétylation of pRb stimulates its binding to proto-oncoprotein Mdm2, providing another 
example whereby acétylation can be involved in regulating protein-protein interaction. 
Furthermore, one report suggested acétylation regulates the stability of E2F-1 (110). Since 
ubiqutination, iSumoylation ; , and acétylation all occur on lysine residues (198), it is possible 
that in some cases, these modifications might antagonise each other and play different roles in 
regulating protein stability. Analysis of acetylated E2F-1 showed it has a more stable half-life 
(110). Interestingly, p53 acétylation was found to be stimulated under certain DNA-damaging 
conditions (139), which were also conditions known to stabilise p53. The functional 
consequence of TFllE and TFIIF acétylation, and the autoacetylation of some HATs, such as 
pCAF and p300/CBP, has not yet been characterised. Nonetheless, an overwhelming picture 
suggests that many non-histone proteins can be acetylated, and acétylation might mimic 
phosphorylation in regulating different aspects of protein activity, and participate in a variety of 
cellular processes.
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pRb acétylation by p300 reveals additional level of control
I reported two functional consequences upon pRb acétylation. First, acetylated pRb had 
higher affinity in binding to oncoprotein MDM2. Most of the known functions of MDM2 were 
ascribed to its ability to regulate p53 stability (53, 101). Biochemical analysis also showed an 
interaction of MDM2 with the pRb/E2F pathway (64, 156, 183). Both pRb and E2F/DP were 
reported to interact with MDM2 (101, 183). MDM2 binds to the C-terminal region of pRb, 
which is also the region acetylated by p300 in vitro. Using biochemical pulldown assays, 1 
demonstrated that MDM2 preferentially associated with the acetylated form of pRb. 
Consistently, MDM2 preferentially associated with pRb in cells treated with TSA. Further 
support came from the observation that there were relatively more MDM2/pRb 
immunocomplexes in 293 HEK cells. 293 HEK cells are transformed with E l A, which is an 
agent identified to stimulate pRb acétylation. In the literature, evidence exists that MDM2 
functions to inactivate pRb by sequestering it away from E2F family protein. At face value, it 
makes sense that a growth-promoting signal, such as E l A, enhances pRb acétylation, thereby 
inactivating its function by stimulating its association with MDM2.
In this thesis, 1 also reported that acétylation of pRb might regulate pRb 
phosphorylation. In an analysis of the pRb acétylation domains in the C-terminus, one region 
was identified which shared a low level of homology with other acetylated substrates. 
Furthermore, this region was previously reported to contain a consensus sequence which was 
required for cyclin-cdk2 mediated phosphorylation of pRb (1). Mutagenesis of the lysine residue 
in this region showed that K873, 874 are possible targets of modification. Furthermore, when 
these lysines were mutated to glutamate, which might mimic the acetylated state, the mutants 
have defects in phosphorylation. Therefore, it suggests that there could be ‘cross-talk’ between
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phosphorylation and acétylation. In this case, acétylation of pRb on K873, 874 may inhibit its 
phosphorylation by cyclin-cdk2.
E l A redirects normal acétylation patterns
Both p300 and pRb were identified as major cellular polypeptides that associate with 
viral oncoprotein E l A. Intriguingly, E l A was reported both to enhance and inhibit p300/pCAF- 
mediated acétylation (2, 25). First, E lA  co-immunoprecipitates with p300/pCAF, which has 
active HAT activity (12). Ait-Si-Ali et al (2) demonstrated that p300/CBP HAT activity peaks at 
G 1/S transition, suggesting the HAT activity is required to drive cells into S phase. Furthermore, 
cyclinE/cdk2 was found to phosphorylate p300 in the C-terminus, which in turn activates p300 
HAT activity (48). Similarly, E lA  enhances p300 HAT activity, suggesting that the viral 
oncoprotein might mimic cellular signals in activating p300 HAT function, thereby driving cells 
into S phase. However, contradictory evidence demonstrated that E lA  represses histone and p53 
acétylation in vitro (25). Noticeably, a very high molar ratio of E lA  to histone was used in those 
assays. The different outcomes observed with E lA  could be due to the different format of the 
assays employed. 1 was very intrigued with E lA ’s ability to regulate pRb acétylation because 
ElA  was known to mediate a ternary complex between p300 and pRb. In addition, this complex 
is important for efficient transformation function of ElA. 1 hypothesized that E lA  enhances pRb 
acétylation, via recruiting p300 and pRb into a trimeric complex, which might have an active 
function in ElA-mediated cellular proliferation. Indeed, biochemical analysis suggests that pRb 
acétylation is stimulated by ElA. A maximum of ten-fold stimulation of pRb acétylation was 
observed. Moreover, E lA  mutants defective in binding to either p300 or pRb failed to enhance 
pRb acétylation. With the same assay, E lA  was found to affect histone acétylation in a 
concentration dependent manner. At low levels, it enhanced histone acétylation to a maximum of 
two-fold. However, as reported in other publications (25, 58), in high concentiations, it repressed
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histone acétylation. It is noted that at similar concentrations of ElA , there was no repression of 
pRb acétylation. In comparative studies, I demonstrated that E2F-1 and p53 acétylation is 
repressed by ElA. ElA, p53 and E2F-1 share over-lapping binding sites on p300, and E lA  can 
inhibit p53 and E2F-1 binding to p300. Therefore, 1 suggest that E lA  has a unique function in 
re-directing p300/CBP HAT activity, presumably in a way which will favour cellular growth and 
proliferation. As with pRb, E lA  actively recruits pRb into complex with p300, and stimulates 
pRb acétylation. Consequently, acetylated pRb might favour cellular growth. Given that there 
are multiple acétylation sites on pRb, it remains to be seen if E lA  favours certain acetylated 
state(s) of pRb. As with E2F-1 and p53, E lA  might act as a competitive inhibitor to prevent their 
association with p300, thereby inhibiting their acétylation. Consistently, in vitro acétylation 
assays carried out on E2F-1 suggested that it is a poor substrate when the minimal HAT domain 
of p300 was used as the enzyme source. However, when the p300 enzyme also contains the E2F 
interaction domain, a much more efficient acétylation of E2F-1 was observed. It was reported 
that p53 acétylation was stimulated under certain DNA damaging condition (100, 139), implying 
that the acetylated p53 might function in growth arrest or apoptosis. Therefore, it is likely that 
E lA  prevents acétylation events which might contribute to growth anest.
p300 in transcription
In order to understand p300 function, a yeast two-hybrid screen was cairied out by 
Shikama et. al. (in press) to identify p300 interacting proteins. One interesting clone identified 
encodes nucleosome assembly protein NAP-2. To this end, 1 was interested in understanding if 
NAP and p300 co-operate in transcriptional regulation. Using biochemical pulldown assays, 1 
identified that NAP binds to the CH3 domain on p300. Conversely, p300 binds to two discrete 
regions on NAP. Further, NAP can dimerise or oligomerise, and two independent domains on 
NAP may mediate this dimérisation. The functional consequence of this dimérisation has not
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been investigated. Using transient transfection assays, I demonstrated that NAP and p300 
augment in transcription activation of an E2F-responsive reporter. Together with the 
observations of my colleagues, we concluded that NAP and p300 synergise in transcriptional 
activation, at least on certain E2F-1 and p53 responsive promoters. In order to understand the 
underlying mechanism, various biochemcial assays were performed, showing NAP, p300 and 
histones can associate in a complex (Shikama et. a l, in press). Furthermore, the NAP-p300 
interaction seems to be enhanced in the presence of histones. Therefore, a simple model suggests 
that NAP might ‘help’ or even target p300 to certain regions of the promoter. Since p300 HAT 
activity is important in transcriptional control, I investigated if NAP can affect this enzymatic 
function. Surprisingly, in vitro assays suggested that NAP inhibits histone acétylation by p300. It 
was not investigated if this also happens in vivo. However, NAP does not inhibit the intrinsic 
HAT activity of p300. Therefore, a more likely scenario is that NAP binds to the histone tails, 
and ‘hides’ the tails from HAT. In a natural promoter context, it is possible that NAP specifically 
recruits p300 to certain promoter regions, allowing p300 to acetylate neighbouring nucleosomes 
for transcriptional modulation. Furthermore, NAP was reported to co-operate with the ISWI 
family of ATPase remodelling complexes in generating regularly spaced nucleosomal arrays 
(70). Together with our finding that p300 associates with NAP, it is possible that NAP might 
function as a ‘bridge’ to associate the ATPase activity and HAT activity, thereby co-ordinate 
these dual enzymatic functions in transcriptional regulation.
Since both NAP and p300 functions were known to be cell cycle regulated (2, 79, 80, 
137), it is possible that these two proteins co-operate in regulating certain classes of genes whose 
expression is cell cycle dependent. It is therefore not surprising to find that NAP and p300 
augment E2F-1 and p53 dependent transcription. Further analysis will be needed to test the 
generality of this hypothesis. Apart from transcription, these protein complexes could also
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participate in chromatin remodelling events related to replication (123), which still remain to be 
explored.
p300 has at least three different modes of regulating transcription: I) as a bridging 
protein to associate DNA-binding factors to the transcriptional apparatus, II) through its HAT 
activity. III) as a assembly platform for multi-protein complex formation. In this study, we 
suggest another mechanism for how this pleiotropic protein can be targeted for transcriptional 
control.
Rb/HDAC: cell cycle arrest or not?
Abundant evidence in the literature ascribes pRb’s tumour suppressive effect to the 
inhibition of E2F-dependent transcription (reviewed in 43, 62, 91, 99, 120, and references 
therein). pRb was found to interact with the rran^activation domain of E2F, providing one 
mechanism of how pRb can inhibit E2F transcriptional activity. However, many E2F DNA 
binding sites are repressive in nature, whose occupancy correlates with transcriptional 
repression. pRb actively represses transcription when artificially tethered to the promoter region 
(30, 177). Using the E2F DNA binding domain as a dominant negative to competitively inhibit 
E2F dependent transcription, it was insufficient to cause several types of G1 arrest (including 
TGFp-, contact inhibition- and pl6- induced cell cycle arrest) (197). Therefore, one hypothesis 
suggested that the E2F/pRb complex recruits other factors to actively repress transcription, 
which may be more relevant to pRb’s function in regulating E2F target genes. Recently, two 
classes of proteins, 1) HDACs and 2) h-SWI/SNF, were shown to bind to pRb to actively repress 
E2F target genes (196). Both proteins possess chromatin-remodelling activity, which may 
account for the underlying repressive mechanisms. Here, by utilizing the three-dimensional 
structure information on the pRb pocket region (94), a series of pocket mutants were generated.
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One such mutant (pRb 6A) lacks the ability to bind to the LXCXE motif, therefore providing an 
invaluable tool in analysing the functional consequence of pRb/HDAC interaction.
First, I demonstrated that the pRb6A mutant had undetectable binding to HDAC. 
Importantly, this mutant is capable of binding to E2F-1 and TAFn250, suggesting its overall 
structure is maintained. Consistently, this mutant repressed E2F-dependent transcription in 
reporter gene assays. Since pRb can block the recruitment of the preinitiation complex of 
TFIIA/TFIID by E2F (138), this provides a mechanism whereby the observed repression might 
be HDAC independent. In order to further analyse the repressive properties of pRb6A, a Gal4- 
6A fusion was generated and this fusion construct showed much reduced repression when 
compared to the wild type Gal4-Rb. This difference could be due to the inability of the mutant to 
recruit HDACs for active repression. When the pRb6A mutant was tested for its ability to cause 
cell cycle anest in SA0S2 cells, it is almost more effective than the wild type pRb. So far, an 
interesting possibility arises is that HDAC may not be required for pRb-mediated G1 arrest in 
SAOS2 cells. A second explanation could be that under over-expression conditions, pRb protein 
maybe expressed at an abnormally high level, which might bypass the need for HDAC for cell 
cycle anest. Further experiments will be required to resolve these issues. Using another 
approach to answer the above question, E2F/HDAC and E2F/pRb hybrids were generated and 
tested for their ability to cause cell cycle arrest (Smith et a l, personal communication). If 
HDAC is important to actively repress E2F target genes for the G I anest, we reasoned that it 
might bypass the need of pRb by fusing HDAC with the DNA binding domain of E2F, therefore 
artificially targeting HDAC to E2F target genes. However, whilst the E2F/pRb hybrid is potent 
in causing G1 arrest in SAOS2 cells, E2F/HDAC hybrid is defective for such function. This 
suggests that HDAC alone may not be sufficient for G1 arrest, and pRb must provide additional 
functions for the observed effects. It is possible that HDAC might contribute toward pRb’s 
growth arrest property under certain specific conditions. As discussed previously, pRb was
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found to be acetylated. Indeed, in vitro assays also suggest that the pRb associated HDAC 
activity can de-acetylate the acetylated pRb (Smith et. a l, personal communication). It has not 
been investigated if acétylation of pRb is cell cycle regulated. A third possibility is that 
pRb/HDAC might regulate other aspects of E2F function. Ecotopic expression of E2F-1 was 
shown to cause extensive apoptosis in SA0S2 cells (65). p300 augments E2F-1 mediated 
apoptosis (92), though the involvement of HAT under those circumstances was not known. pRb 
can counteract E2F-1 mediated apoptosis (65). It is possible that HDAC might be involved in 
this process, perhaps by co-operating with pRb in rescuing E2F-dependent apoptosis. Further 
experimentation will be heeded to verify, and eliminate these possibilities.
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